Downtime Plans Treatment & Therapy Plans
Loading Documents
-
- CLL IP BENDAMUSTINE 100 / RITUXIMAB 375 (START ON DAY 1)
- CLL IP BENDAMUSTINE 100 / RITUXIMAB 375 (START ON DAY 2)
- H-39444 BMT CTN 1503 (STRIDE 2) SCREENING VISIT
- IP / OP RESEARCH PRO00021862 / BERNICKER IMCGP100 ARM 1
- IP / OP RESEARCH PRO00031115 / BERNICKER IMCGP100 TEBENTAFUSP EXPANDED ACCESS
- IP / OP RESEARCH PRO00032110 / BERNICKER IMCGP100 TEBENTAFUSP EXPANDED ACCESS
- IP / OP RESEARCH PRO00033129 / BERNICKER IMCGP100 TEBENTAFUSP EXPANDED ACCESS
- IP / OP RSH PRO00036343 / IMCGP100-203 / ARM A / TEBENTAFUSP
- IP / OP RSH PRO00036343 / IMCGP100-203 / ARM B
- IP / OP VAC IE EVERY 14 DAYS (INTERVAL COMPRESSED)
- IP / OP VAC IE EVERY 21 DAYS
- IP 5FU (CONCURRENT WITH RADIATION)
- IP 5FU / LEUCOVORIN (EVERY 14 DAYS)
- IP 5FU / MITOMYCIN (CONCURRENT WITH RADIATION)
- IP ABVD
- IP AC
- IP AC (DOSE DENSE)
- IP ADO-TRASTUZUMAB EMTANSINE
- IP AIM
- IP ALEMTUZUMAB
- IP APL INDUCTION (LOW/INTERMEDIATE)
- IP APLASTIC ANEMIA – ATG/CSA
- IP APML4 FIRST CONSOLIDATION
- IP APML4 INDUCTION
- IP AUGMENTED CVAD / PEGASPARGASE (C-VAD DRUGS / PART A) / (ARA-C/MTX/VINC DRUGS / PART B)
- IP AVD / BRENTUXIMAB
- IP AYA REMISSION INDUCTION (CALGB 10403)
- IP AZACITIDINE (5 DAYS)
- IP AZACITIDINE (7 DAYS)
- IP BEACOPP
- IP BENDAMUSTINE / BORTEZOMIB / PREDNISONE
- IP BEP
- IP BEVACIZUMAB 10MG/KG EVERY 14 DAYS
- IP BLINATUMOMAB
- IP BORTEZOMIB (EVERY 14 DAYS)
- IP BORTEZOMIB / DEXAMETHASONE (EVERY 21 DAYS)
- IP BORTEZOMIB / DEXAMETHASONE (EVERY 7 DAYS)
- IP BORTEZOMIB / DEXAMETHASONE / CYCLOPHOSHAMIDE
- IP BRENTUXIMAB VEDOTIN
- IP CABAZITAXEL
- IP CAGT ALLOGENEIC SCT (HAPLO) MEL-FLU WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
- IP CAGT ALLOGENEIC SCT BU-CY (WITH TACROLIMUS & MINI METHOTREXATE GVHD PROPHYLAXIS)
- IP CAGT ALLOGENEIC SCT BU-FLU (WITH TACROLIMUS & MINI METHOTREXATE GVHD PROPHYLAXIS)
- IP CAGT ALLOGENEIC SCT CAMGRAFT
- IP CAGT ALLOGENEIC SCT CY-TBI
- IP CAGT ALLOGENEIC SCT CY-TBI-CAM
- IP CAGT ALLOGENEIC SCT FLU-MEL (WITH TACROLIMUS & MINI METHOTREXATE GVHD PROPHYLAXIS)
- IP CAGT ALLOGENEIC SCT FLU-MEL-CAM
- IP CAGT ALLOGENEIC SCT FLU-MEL-PTCY
- IP CAGT ALLOGENEIC SCT IV BU-CY-CAM
- IP CAGT ALLOGENEIC SCT IV BU-FLU-CAM
- IP CAGT ALLOGENEIC SCT IV BU-FLU-PTCY
- IP CAGT ALLOGENEIC SCT IV CLO-BU-CAM
- IP CAGT ALLOGENEIC SCT SAAMUD
- IP CAGT AUTOLOGOUS MOBILIZATION CYTARABINE
- IP CAGT AUTOLOGOUS MOBILIZATION HIGH DOSE CYCLOPHOSPHAMIDE
- IP CAGT AUTOLOGOUS SCT HIGH DOSE ETOPOSIDE / CARBOPLATIN (EINHORN PROTOCOL)
- IP CAGT AUTOLOGOUS SCT HIGH DOSE ETOPOSIDE / CARBOPLATIN (TICE PROTOCOL)
- IP CAGT AUTOLOGOUS SCT HIGH DOSE MELPHALAN
- IP CAGT AUTOLOGOUS SCT IV BEAM
- IP CAGT AUTOLOGOUS SCT IV BEAM-R
- IP CAGT AUTOLOGOUS SCT IV CARMUSTINE / THIOTEPA (MATRIX)
- IP CAGT R-IE
- IP CARBOPLATIN (AUC =6) / DOCETAXEL 75 MG/M2
- IP CARBOPLATIN (AUC=2) / GEMCITABINE (EVERY 21 DAYS)
- IP CARBOPLATIN (AUC=4) / GEMCITABINE 1000 / BEVACIZUMAB 15
- IP CARBOPLATIN (AUC=5) / GEMCITABINE 1000 MG/M2
- IP CARBOPLATIN (AUC=5) / LIPOSOMAL DOXORUBICIN 30
- IP CARBOPLATIN (AUC=6) / PACLITAXEL 175 (GYNECOLOGIC)
- IP CARBOPLATIN / ETOPOSIDE (EVERY 21 DAYS)
- IP CARBOPLATIN / GEMCITABINE
- IP CARBOPLATIN / NAB-PACLITAXEL
- IP CARBOPLATIN / PACLITAXEL (DOSE DENSE)
- IP CARBOPLATIN / PACLITAXEL (LUNG)
- IP CARBOPLATIN / PACLITAXEL / BEVACIZUMAB
- IP CARBOPLATIN / PACLITAXEL / BEVACIZUMAB (DOSE DENSE)
- IP CARBOPLATIN / PACLITAXEL W/ CONCURRENT THORACIC RT
- IP CARBOPLATIN / PEMETREXED
- IP CARBOPLATIN / PEMETREXED / BEVACIZUMAB
- IP CARBOPLATIN DESENSITIZATION
- IP CARFILZOMIB (INITIAL CYCLE)
- IP CARFILZOMIB (MAINTENANCE)
- IP CEOP
- IP CETUXIMAB (EVERY 14 DAYS)
- IP CETUXIMAB (INITIAL DOSE) (EVERY 7 DAYS)
- IP CETUXIMAB (MAINTENANCE DOSE) (EVERY 7 DAYS)
- IP CHOP
- IP CIA
- IP CISPLATIN / DOCETAXEL (EVERY 21 DAYS)
- IP CISPLATIN / DOCETAXEL / 5FU
- IP CISPLATIN / DOXORUBICIN
- IP CISPLATIN / DOXORUBICIN + DEXRAZOXANE
- IP CISPLATIN / ETOPOSIDE (EVERY 21 DAYS)
- IP CISPLATIN / ETOPOSIDE W/ CONCURRENT THORACIC RT (EVERY 21 DAYS)
- IP CISPLATIN / GEMCITABINE (EVERY 21 DAYS)
- IP CISPLATIN / GEMCITABINE (EVERY 28 DAYS)
- IP CISPLATIN / IRINOTECAN (EVERY 21 DAYS – D1,D8)
- IP CISPLATIN / PACLITAXEL
- IP CISPLATIN / PACLITAXEL (INTRAPERITONEAL)
- IP CISPLATIN / PACLITAXEL / BEVACIZUMAB
- IP CISPLATIN / PEMETREXED
- IP CISPLATIN / PEMETREXED W/ CONCURRENT THORACIC RT
- IP CISPLATIN / VINORELBINE (EVERY 21 DAYS)
- IP CISPLATIN 20 MG/M2 (EVERY 7 DAYS)
- IP CISPLATIN 25 MG/M2 (EVERY 7 DAYS)
- IP CISPLATIN 60 / ETOPOSIDE 100 (EVERY 21 DAYS)
- IP CISPLATIN 75 MG/M2 (EVERY 21 DAYS)
- IP CISPLATIN W/ CONCURRENT RT (EVERY 7 DAYS)
- IP CLADRIBINE 0.09 (7 DAYS)
- IP CLADRIBINE 0.14 (DAILY)
- IP CLADRIBINE 0.15 (WEEKLY)
- IP CLAG
- IP CLIA
- IP CLOFARABINE / CYTARABINE
- IP CODOX A
- IP CODOX B
- IP CYBORDEX
- IP CYCLOPHOSPHAMIDE / VINCRISTINE / MERCAPTOPURINE / CYTARABINE / PEGASPARGASE
- IP CYTARABINE / DAUNORUBICIN / GEMTUZUMAB (7+3)
- IP CYTARABINE / IDARUBICIN (7+3)
- IP CYTARABINE 100 / DAUNORUBICIN 60 (7 + 3)
- IP DARATUMUMAB
- IP DEANGELIS – METHOTREXATE / VINCRISTINE / LEUCOVORIN / PROCARBAZINE (CYCLES 1,3,5)
- IP DEANGELIS WITH RITUXIMAB – METHOTREXATE / VINCRISTINE / LEUCOVORIN (CYCLES 2 AND 4)
- IP DEANGELIS WITH RITUXIMAB – METHOTREXATE / VINCRISTINE / LEUCOVORIN / PROCARBAZINE (CYCLES 1,3,5)
- IP DECITABINE (28 DAYS)
- IP DECITABINE (42 DAYS)
- IP DHAP
- IP DOCETAXEL
- IP DOCETAXEL / CAPECITABINE
- IP DOCETAXEL 30 MG/M2 (EVERY 21 DAYS)
- IP DOCETAXEL 75 MG/M2 (EVERY 21 DAYS)
- IP DOF (DOCETAXEL / OXALIPLATIN / FLUOROURACIL) (EVERY 14 DAYS)
- IP EC (100/830)
- IP EC (75/600)
- IP EOF (EPIRUBICIN / OXALIPLATIN / FLUOROURACIL)
- IP EP
- IP EPOCH
- IP ERIBULIN
- IP ESHAP
- IP FEC (EVERY 21 DAYS)
- IP FLAG-IDA
- IP FLAG-IDA CONSOLIDATION
- IP FLAT DOSE CYTARABINE
- IP FLUDARABINE / CYCLOPHOSPHAMIDE / RITUXIMAB
- IP FOLFIRI (EVERY 14 DAYS)
- IP FOLFIRI / BEVACIZUMAB (EVERY 14 DAYS)
- IP FOLFIRI / CETUXIMAB (INITIAL DOSE) (EVERY 14 DAYS)
- IP FOLFIRI / CETUXIMAB 400 MG/M2 (EVERY 14 DAYS)
- IP FOLFIRI / CETUXIMAB 500 MG/M2 (EVERY 14 DAYS)
- IP FOLFIRI / PANITUMUMAB
- IP FOLFIRI / RAMUCIRUMAB
- IP FOLFIRI / ZIV-AFLIBERCEPT (EVERY 14 DAYS)
- IP FOLFIRINOX (EVERY 14 DAYS)
- IP FOLFOXIRI (EVERY 14 DAYS)
- IP FOLFOXIRI (EVERY 14 DAYS) WITH CETUXIMAB (DAY 1 AND DAY 8)
- IP FOLFOXIRI / BEVACIZUMAB (EVERY 14 DAYS)
- IP FOLFOXIRI / CETUXIMAB (EVERY 14 DAYS)
- IP FOLFOXIRI / PANITUMUMAB (EVERY 14 DAYS)
- IP FOLFOXIRI / ZIV-AFLIBERCEPT (EVERY 14 DAYS)
- IP GDP
- IP GEMCITABINE / CISPLATIN (EVERY 21 DAYS)
- IP GEMCITABINE / CISPLATIN (EVERY 21 DAYS) (LUNG)
- IP GEMCITABINE / CISPLATIN (SPLIT DOSE)
- IP GEMCITABINE / DOCETAXEL
- IP GEMCITABINE / VINORELBINE / DOXORUBICIN LIPOSOMAL
- IP GEMCITABINE 1000 (EVERY 28 DAYS)
- IP GEMCITABINE 1000 MG/M2 (EVERY 21 DAYS)
- IP GEMCITABINE 675 EVERY 28 DAYS)
- IP GEMCITABINE 800 (EVERY 7 DAYS)
- IP GEMCITABINE 800 MG/M2 (EVERY 21 DAYS)
- IP GEMOX (675/80)
- IP HIDAC (D1,3,5)
- IP HIDAC (D1,3,5) / DAUNORUBICIN
- IP HIDAC (D1,3,5) / IDARUBICIN
- IP HIGH DOSE METHOTREXATE / LEUCOVORIN (DAY 2)
- IP HYPERCVAD A AND B (ALTERNATING)
- IP ICE
- IP IFOSFAMIDE / ETOPOSIDE
- IP INOTUZUMAB OZOGAMICIN CONSOLIDATION
- IP INOTUZUMAB OZOGAMICIN INDUCTION
- IP INTRATHECAL CHEMOTHERAPY
- IP IRINOTECAN / CETUXIMAB / VEMURAFENIB (EVERY 14 DAYS)
- IP IROX
- IP IXABEPILONE
- IP LIPOSOMAL DOXORUBICIN (EVERY 14 DAYS)
- IP LIPOSOMAL DOXORUBICIN (EVERY 28 DAYS)
- IP LIPOSOMAL DOXORUBICIN / BEVACIZUMAB
- IP LIPOSOMAL IRINOTECAN / LEUCOVORIN / FLUOROURACIL
- IP MEC (5 DAYS)
- IP MFOLFOX6 (EVERY 14 DAYS)
- IP MFOLFOX6 (EVERY 14 DAYS) / CETUXIMAB D1, 8
- IP MFOLFOX6 / BEVACIZUMAB (EVERY 14 DAYS)
- IP MFOLFOX6 / CETUXIMAB (EVERY 14 DAYS)
- IP MFOLFOX6 / CETUXIMAB (LOADING DOSE) (EVERY 7 DAYS) (14 DAY CYCLE)
- IP MFOLFOX6 / PANITUMUMAB
- IP MFOLFOX6 / ZIV-AFLIBERCEPT (EVERY 14 DAYS)
- IP MINICHOP
- IP MODIFIED CYBORDEX
- IP MODIFIED FOLFIRINOX (EVERY 2 WEEKS)
- IP MOXETUMOMAB EVERY 28 DAYS
- IP MVAC (DOSE DENSE)
- IP NAB-PACLITAXEL
- IP NAB-PACLITAXEL (EVERY 7 DAYS)
- IP NAB-PACLITAXEL / GEMCITABINE
- IP NAB-PACLITAXEL / GEMCITABINE (DOSE-REDUCED) (EVERY 28 DAYS)
- IP O-FC (CYCLE 1 ONLY)
- IP O-FC (CYCLE 2 AND BEYOND)
- IP OBINUTUZUMAB / CHLORAMBUCIL (CYCLE 1 ONLY)
- IP OFATUMUMAB (CYCLE 1 ONLY)
- IP OFATUMUMAB WEEKLY (REFRACTORY)
- IP OXALIPLATIN DESENSITIZATION
- IP PACLITAXEL (DOSE DENSE) EVERY 21 DAYS
- IP PACLITAXEL 80 (EVERY 21 DAYS)
- IP PACLITAXEL 80 (EVERY 28 DAYS)
- IP PACLITAXEL 80 (EVERY 7 DAYS)
- IP PAD
- IP PANITUMUMAB
- IP PEMETREXED
- IP PENTOSTATIN
- IP PRALATREXATE
- IP PRO00037588 IOV-GM1-201 GANGULY
- IP R-CEOP
- IP R-CHOP
- IP R-CVP
- IP R-DHAP
- IP R-EPOCH
- IP R-ESHAP
- IP R-HIGH DOSE METHOTREXATE / LEUCOVORIN (DAY 2)
- IP R-HYPERCVAD A AND B (ALTERNATING)
- IP R-ICE
- IP R-MINICHOP
- IP RAMUCIRUMAB (EVERY 14 DAYS)
- IP RAMUCIRUMAB / DOCETAXEL (EVERY 21 DAYS)
- IP RAMUCIRUMAB / PACLITAXEL (EVERY 28 DAYS)
- IP RESEARCH / HILL CTL H-43761 CRIMSON-NE
- IP RESEARCH / HILL H-48389 ALTRUBIO – MULTIPLE DOSE (PK SUBJECTS)
- IP RESEARCH / HILL H-48389 ALTRUBIO – MULTIPLE DOSE (RETREATMENT)
- IP RESEARCH / HILL H-48389 ALTRUBIO – MULTIPLE DOSE PHASE
- IP RESEARCH BMT CTN 1705 (H-46470)
- IP RESEARCH PRO00035985 EA9181 NCT04530565 ARM B (AGE > 70 OR YOUNGER, UNFIT PATIENT) SHAH
- IP RESEARCH PRO00035985 EA9181 NCT04530565 ARM B (FIT PATIENTS AGES 18-70) SHAH
- IP RESEARCH PRO00035985 EA9181 NCT04530565 ARM C INTENSIFICATION SHAH
- IP RESEARCH PRO00035985 EA9181 NCT04530565 ARM E (AGE > 70 OR YOUNGER, UNFIT PATIENT) SHAH
- IP RESEARCH PRO00035985 EA9181 NCT04530565 ARM E (FIT PATIENTS AGES 18-70) SHAH
- IP RITUXIMAB 375 (WEEKLY)
- IP RITUXIMAB 375 / BORTEZOMIB (CYCLE 1 ONLY)
- IP RITUXIMAB 375 / BORTEZOMIB (CYCLE 2 AND BEYOND)
- IP ROMIDEPSIN
- IP TAC
- IP TC
- IP TCH (LOADING DOSE ONLY)
- IP TCH (MAINTENANCE REGIMEN)
- IP TECLISTAMAB-CQYV
- IP TEMOZOLOMIDE / RITUXIMAB
- IP TFOX (EVERY 14 DAYS)
- IP TIP (GERM-CELL TUMORS)
- IP TOPOTECAN (DAILY)
- IP TOPOTECAN (EVERY 21 DAYS – D1,D8,D15)
- IP TOPOTECAN (WEEKLY)
- IP TOPOTECAN / BEVACIZUMAB
- IP TOPOTECAN / BEVACIZUMAB (EVERY 7 DAYS)
- IP TRABECTEDIN
- IP TRASTUZUMAB (EVERY 21 DAYS) LOADING DOSE
- IP TRASTUZUMAB (EVERY 7 DAYS)
- IP TRASTUZUMAB / LAPATINIB (CYCLE 1 ONLY)
- IP TRASTUZUMAB / LAPATINIB (CYCLE 2 AND BEYOND)
- IP TRASTUZUMAB / PACLITAXEL (EVERY 7 DAYS)
- IP TRASTUZUMAB / PERTUZUMAB / DOCETAXEL (CYCLE 1 ONLY)
- IP TRASTUZUMAB / PERTUZUMAB / DOCETAXEL (CYCLE 2 AND BEYOND)
- IP TRASTUZUMAB / PERTUZUMAB / DOCETAXEL / CARBOPLATIN (LOADING DOSE ONLY)
- IP TRASTUZUMAB / PERTUZUMAB / DOCETAXEL / CARBOPLATIN (MAINTENANCE REGIMEN)
- IP TRASTUZUMAB / PERTUZUMAB / PACLITAXEL (CYCLE 1 ONLY)
- IP TRASTUZUMAB / PERTUZUMAB / PACLITAXEL (CYCLE 2 AND BEYOND)
- IP TRASTUZUMAB 6 (EVERY 21 DAYS) MAINTENANCE DOSE
- IP V-DCEP
- IP VAC (ALTERNATING WITH IE)
- IP VAD
- IP VD-PACE
- IP VINCRISTINE (EVERY 28 DAYS)
- IP VINORELBINE (EVERY 7 DAYS)
- IP VIP
- IP VYXEOS CONSOLIDATION
- IP VYXEOS INDUCTION
- IP WEEKLY IRINOTECAN / FLUOROURACIL / LEUCOVORIN (EVERY 28 DAYS)
- IP XELIRI (EVERY 21 DAYS)
- IP XELIRI / BEVACIZUMAB (EVERY 21 DAYS)
- IP XELIRI / CETUXIMAB (EVERY 21 DAYS)
- IP XELIRI / PANITUMUMAB
- IP XELIRI / ZIV-AFLIBERCEPT
- IP XELOX (EVERY 21 DAYS)
- IP XELOX (EVERY 21 DAYS) + CETUXIMAB D1, 8, 15
- IP XELOX + BEVACIZUMAB (EVERY 21 DAYS)
- IP XELOX / ZIV-AFLIBERCEPT (EVERY 21 DAYS)
- IP/OP BIWEEKLY TALQUETAMAB-TGVS (TALVEY)
- IP/OP EMA-CO
- IP/OP HYPERFRACTIONATED CYCLOPHOSPHAMIDE
- IP/OP RESEARCH PRO00035531 / GANGULY TNB383B.0001 PHASE I ARM E
- IP/OP RESEARCH PRO00035735 ANHL1931 PINGALI ARM A
- IP/OP RESEARCH PRO00035735 ANHL1931 PINGALI ARM B
- IP/OP RESEARCH PRO00035985 EA9181 NCT04530565 ARM C SHAH
- IP/OP RESEARCH PRO00035985 EA9181 NCT04530565 ARM D SHAH
- IP/OP RESEARCH PRO00037627 / GANGULY P-BCMA-ALL01 OPEN-LABEL, PHASE I ARM P1
- IP/OP RESEARCH PRO00037627 / GANGULY P-BCMA-ALL01 OPEN-LABEL, PHASE I ARM P1.5
- IP/OP RESEARCH PRO00037922 / GANGULY PFIZER C1071032 OPEN-LABEL ELRANATAMAB ARM A
- IP/OP RSH CILESTE/ H-47906
- IP/OP RSH PRO00035986 / EA9152 / ARM D
- IP/OP TEBENTAFUSP-TEBN
- IP/OP WEEKLY TALQUETAMAB-TGVS (TALVEY)
- NHL IP BENDAMUSTINE 120 / RITUXIMAB 375 (START ON DAY 1)
- NHL IP BENDAMUSTINE 120 / RITUXIMAB 375 (START ON DAY 2)
- NHL IP BENDAMUSTINE 90 / RITUXIMAB 375 (START ON DAY 1)
- NHL IP BENDAMUSTINE 90 / RITUXIMAB 375 (START ON DAY 2)
- OP 5FU / LEUCOVORIN (EVERY 14 DAYS)
- OP 5FU / MITOMYCIN (CONCURRENT WITH RADIATION)
- OP 5FU CONTINUOUS INFUSION (CONCURRENT WITH RADIATION)
- OP ABVD
- OP AC
- OP AC (DOSE DENSE)
- OP AC + PEMBROLIZUMAB
- OP ADO-TRASTUZUMAB EMTANSINE (CYCLE 1 AND CYCLE 2-4)
- OP AIM
- OP ALEMTUZUMAB
- OP AMIVANTAMAB – VMJW
- OP APML4 MAINTENANCE
- OP APML4 SECOND CONSOLIDATION
- OP ARSENIC TRIOXIDE CONSOLIDATION
- OP ARSENIC TRIOXIDE INDUCTION
- OP ARSENIC TRIOXIDE MAINTENANCE (EVERY 28 DAYS)
- OP ATEZOLIZUMAB
- OP ATEZOLIZUMAB / BEVACIZUMAB (EVERY 21 DAYS)
- OP ATEZOLIZUMAB / NAB-PACLITAXEL EVERY 28 DAYS
- OP ATEZOLIZUMAB 1680 MG EVERY 28 DAYS
- OP AVD / BRENTUXIMAB
- OP AVELUMAB (Q14 DAYS)
- OP AYA – COURSE 1 (REMISSION INDUCTION)
- OP AYA – COURSE 1A (EXTENDED REMISSION INDUCTION)
- OP AYA – COURSE 2 (REMISSION CONSOLIDATION)
- OP AYA – COURSE 3 (INTERIM MAINTENANCE)
- OP AYA – COURSE 4 (DELAYED INTENSIFICATION)
- OP AYA – COURSE 5 (MAINTENANCE THERAPY)
- OP AZACITIDINE (5 DAYS)
- OP AZACITIDINE (7 DAYS)
- OP BCG VIA FOLEY CATHETER FOR LOW TO IMMEDIATE RISK LOCALIZED UROTHELIAL CANCER
- OP BCG VIA NEPHROSTOMY TUBE
- OP BEACOPP
- OP BELANTAMAB MAFODOTIN-BLMF EVERY 21 DAYS
- OP BELINOSTAT
- OP BENDAMUSTINE / BORTEZOMIB / PREDNISONE
- OP BENDAMUSTINE / RITUXIMAB (DAY 1 START) (CLL)
- OP BENDAMUSTINE / RITUXIMAB (DAY 1 START) (NHL) EVERY 21 DAYS
- OP BENDAMUSTINE / RITUXIMAB (DAY 1 START) (NHL) EVERY 28 DAYS
- OP BENDAMUSTINE / RITUXIMAB (DAY 2 START) (CLL)
- OP BENDAMUSTINE / RITUXIMAB (DAY 2 START) (NHL) EVERY 21 DAYS
- OP BENDAMUSTINE / RITUXIMAB (DAY 2 START) (NHL) EVERY 28 DAYS
- OP BEP
- OP BEVACIZUMAB 10 EVERY 14 DAYS
- OP BEVACIZUMAB 15 EVERY 21 DAYS
- OP BICNU, CISPLATIN & VINCRISTINE FOR MEDULLOBLASTOMA
- OP BLANK CHEMOTHERAPY PROTOCOL TEMPLATE
- OP BORTEZOMIB (EVERY 21 DAYS)
- OP BORTEZOMIB (EVERY 7 DAYS)
- OP BORTEZOMIB / LIPOSOMAL DOXORUBICIN
- OP BORTEZOMIB MAINTENANCE (EVERY 14 DAYS)
- OP BRENTUXIMAB VEDOTIN
- OP CABAZITAXEL
- OP CAGT AUTOLOGOUS MOBILIZATION HIGH DOSE CYCLOPHOSPHAMIDE
- OP CAGT AUTOLOGOUS SCT IV RITUXIMAB (BEAM-R)
- OP CAGT CYCLOPHOSPHAMIDE / FLUDARABINE
- OP CAGT CYCLOPHOSPHAMIDE / FLUDARABINE / TISAGENLECLEUCEL – ACUTE LYMPHOCYTIC LEUKEMIA (ALL)
- OP CAGT CYCLOPHOSPHAMIDE / FLUDARABINE / TISAGENLECLEUCEL – DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
- OP CAGT CYCLOPHOSPHAMIDE / FLUDARABINE LYMPHODEPLETION – MAGENTA
- OP CAGT CYCLOPHOSPHAMIDE / FLUDARABINE LYMPHODEPLETION – RELY-30
- OP CAGT CYCLOPHOSPHAMIDE / FLUDARABINE LYMPHODEPLETION – VEGAS
- OP CAGT CYCLOPHOSPHAMIDE / FLUDARABINE/NIVOLUMAB LYMPHODEPLETION – HESTIA
- OP CAGT CYCLOPHOSPHAMIDE/FLUDARABINE/AXICABTAGENE CILOLEUCEL– DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
- OP CAGT NIVOLUMAB – PREVALE
- OP CAGT R-IE
- OP CAP
- OP CAPECITABINE
- OP CARBOPLATIN (AUC = 2) / NAB-PACLITAXEL (DAY 1 & 8 ONLY) / PEMBROLIZUMAB
- OP CARBOPLATIN (AUC = 4) / GEMCITABINE
- OP CARBOPLATIN (AUC = 5) / ETOPOSIDE / ATEZOLIZUMAB (EVERY 21 DAYS)
- OP CARBOPLATIN (AUC = 5) / GEMCITABINE
- OP CARBOPLATIN (AUC = 5) / GEMCITABINE / NIVOLUMAB (LUNG CANCER)
- OP CARBOPLATIN (AUC = 5) / PACLITAXEL (BREAST)
- OP CARBOPLATIN (AUC = 5) / WEEKLY PACLITAXEL / PEMBROLIZUMAB
- OP CARBOPLATIN (AUC = 6) / PACLITAXEL / BEVACIZUMAB / ATEZOLIZUMAB
- OP CARBOPLATIN (AUC = 6) / PACLITAXEL / NIVOLUMAB (LUNG CANCER)
- OP CARBOPLATIN (AUC =6) / PACLITAXEL / PEMBROLIZUMAB CYCLE 1-4 FOLLOWED BY PEMBROLIZUMAB
- OP CARBOPLATIN / CETUXIMAB
- OP CARBOPLATIN / DOCETAXEL
- OP CARBOPLATIN / ETOPOSIDE (EVERY 21 DAYS)
- OP CARBOPLATIN / ETOPOSIDE W/ ACC HYPERFX RADIATION
- OP CARBOPLATIN / GEMCITABINE (EVERY 7 DAYS)
- OP CARBOPLATIN / GEMCITABINE / BEVACIZUMAB
- OP CARBOPLATIN / LIPOSOMAL DOXORUBICIN
- OP CARBOPLATIN / NAB-PACLITAXEL
- OP CARBOPLATIN / NAB-PACLITAXEL / PEMBROLIZUMAB
- OP CARBOPLATIN / PACLITAXEL (DOSE DENSE)
- OP CARBOPLATIN / PACLITAXEL (GYNECOLOGIC)
- OP CARBOPLATIN / PACLITAXEL (LUNG)
- OP CARBOPLATIN / PACLITAXEL / BEVACIZUMAB
- OP CARBOPLATIN / PACLITAXEL / BEVACIZUMAB (DOSE DENSE)
- OP CARBOPLATIN / PACLITAXEL W/ CONCURRENT THORACIC RT
- OP CARBOPLATIN / PEMETREXED
- OP CARBOPLATIN / PEMETREXED / BEVACIZUMAB
- OP CARBOPLATIN AUC = 4 / CABAZITAXEL
- OP CARBOPLATIN W/ CONCURRENT THORACIC RT
- OP CARFILZOMIB (INITIAL AND MAINTENANCE)
- OP CARFILZOMIB (INITIAL CYCLE)
- OP CARFILZOMIB (MAINTENANCE)
- OP CARFILZOMIB (WEEKLY)
- OP CARMUSTINE / BEVACIZUMAB EVERY 42 DAYS
- OP CEMIPLIMAB (EVERY 21 DAYS)
- OP CEOP
- OP CETUXIMAB (EVERY 14 DAYS)
- OP CETUXIMAB (EVERY 2 WEEKS) / PEMBROLIZUMAB (EVERY 6 WEEKS)
- OP CETUXIMAB (EVERY 7 DAYS)
- OP CHOEP (EVERY 21 DAYS)
- OP CHOP
- OP CIA
- OP CISPLATIN (EVERY 21 DAYS)
- OP CISPLATIN / CETUXIMAB
- OP CISPLATIN / DOCETAXEL (EVERY 21 DAYS)
- OP CISPLATIN / DOCETAXEL / 5FU
- OP CISPLATIN / DOXORUBICIN
- OP CISPLATIN / ETOPOSIDE (EVERY 21 DAYS) 60/100
- OP CISPLATIN / ETOPOSIDE (EVERY 21 DAYS) 75/100
- OP CISPLATIN / ETOPOSIDE W/ CONCURRENT THORACIC RT (EVERY 21 DAYS)
- OP CISPLATIN / ETOPOSIDE W/ CONCURRENT THORACIC RT (EVERY 28 DAYS)
- OP CISPLATIN / GEMCITABINE (EVERY 28 DAYS)
- OP CISPLATIN / IRINOTECAN (EVERY 21 DAYS – D1,D8)
- OP CISPLATIN / IRINOTECAN (EVERY 21 DAYS – D1,D8,D15)
- OP CISPLATIN / PACLITAXEL
- OP CISPLATIN / PACLITAXEL / BEVACIZUMAB
- OP CISPLATIN / PEMETREXED
- OP CISPLATIN / PEMETREXED / NIVOLUMAB (LUNG CANCER)
- OP CISPLATIN / PEMETREXED W/ CONCURRENT THORACIC RT
- OP CISPLATIN / VINORELBINE (EVERY 21 DAYS)
- OP CISPLATIN 20 MG/M2 (EVERY 7 DAYS)
- OP CISPLATIN 25 MG/M2 (EVERY 7 DAYS)
- OP CISPLATIN W/ CONCURRENT RT (EVERY 21 DAYS)
- OP CISPLATIN W/ CONCURRENT RT (EVERY 7 DAYS)
- OP CLADRIBINE (DAILY)
- OP CLADRIBINE (WEEKLY)
- OP CLOFARABINE / CYTARABINE
- OP CMF
- OP COPP
- OP CVP
- OP CYBORDEX
- OP CYCLOPHOSPHAMIDE / VINCRISTINE / MERCAPTOPURINE / CYTARABINE / PEGASPARGASE
- OP DARATUMUMAB
- OP DARATUMUMAB / BORTEZOMIB / DEXAMETHASONE
- OP DARATUMUMAB-HYALURONIDASE (DARZALEX FASPRO)
- OP DARATUMUMAB-HYALURONIDASE-FIHJ / BORTEZOMIB / DEXAMETHASONE (GRIFFIN TRIAL)
- OP DARATUMUMAB-HYALURONIDASE-FIHJ / CARFILZOMIB / DEXAMETHASONE (CANDOR TRIAL) EVERY 28 DAYS
- OP DARZALEX FASPRO + CYBORDEX (ANDROMEDA PROTOCOL)
- OP DARZALEX FASPRO + CYBORDEX (LYRA PROTOCOL)
- OP DECITABINE (28 DAYS)
- OP DECITABINE (42 DAYS)
- OP DOCETAXEL
- OP DOCETAXEL (EVERY 21 DAYS)
- OP DOCETAXEL / CAPECITABINE
- OP DOXORUBICIN 75 MG/M2 BOLUS /IFOSFAMIDE 10 G/M2 OVER 4 DAYS/ MESNA CIV
- OP DOXORUBICIN 75 MG/M2 BOLUS /IFOSFAMIDE 10 G/M2 OVER 5 DAYS/ MESNA BOLUS
- OP DOXORUBICIN 75 MG/M2 CIV /IFOSFAMIDE 10 G/M2 OVER 5 DAYS/ MESNA BOLUS
- OP DOXORUBICIN/TRABECTEDIN INDUCTION
- OP DURVALUMAB (FLAT DOSE 1500 MG) EVERY 4 WEEKS
- OP DURVALUMAB WEIGHT BASED DOSE (EVERY 14 DAYS)
- OP DURVALUMAB/GEMCITABINE/CISPLATIN X 8 CYCLES (EVERY 21 DAYS) THEN DURVALUMAB MAINTENANCE (EVERY 28 DAYS) (CHOLANGIOCARCINOMA)
- OP DVD (LOW DOSE)
- OP DVD-R
- OP EC (100/830)
- OP EC (75/600)
- OP ELOTUZUMAB
- OP ENFORTUMAB VEDOTIN / PEMBROLIZUMAB EVERY 21 DAYS
- OP ENFORTUMAB VEDOTIN-EJFV EVERY 28 DAYS
- OP EOF
- OP EP
- OP ERIBULIN
- OP ETOPOSIDE / CISPLATIN / CYCLOPHOSPHAMIDE
- OP FAC (EVERY 21 DAYS)
- OP FAM-TRASTUZUMAB DERUXTECAN EVERY 21 DAYS
- OP FAM-TRASTUZUMAB DERUXTECAN EVERY 21 DAYS FOR GI MALIGNANCY
- OP FEC (EVERY 21 DAYS)
- OP FLA
- OP FLAG-IDA
- OP FLOT
- OP FLUDARABINE / CYCLOPHOSPHAMIDE / RITUXIMAB
- OP FOLFIRI (EVERY 14 DAYS)
- OP FOLFIRI / BEVACIZUMAB (EVERY 14 DAYS)
- OP FOLFIRI / CETUXIMAB (EVERY 14 DAYS)
- OP FOLFIRI / CETUXIMAB (EVERY 7 DAYS)
- OP FOLFIRI / PANITUMUMAB
- OP FOLFIRI / RAMUCIRUMAB
- OP FOLFIRI / ZIV-AFLIBERCEPT (EVERY 14 DAYS)
- OP FOLFOX PLUS XRT (ESOPHAGEAL CANCER – DEFINITIVE CHEMORADIATION)
- OP FOLFOXIRI (EVERY 14 DAYS)
- OP FOLFOXIRI (EVERY 14 DAYS) / CETUXIMAB (EVERY 7 DAYS)
- OP FOLFOXIRI / BEVACIZUMAB (EVERY 14 DAYS)
- OP FOLFOXIRI / CETUXIMAB (EVERY 14 DAYS)
- OP FOLFOXIRI / PANITUMUMAB (EVERY 14 DAYS)
- OP FOLFOXIRI / ZIV-AFLIBERCEPT (EVERY 14 DAYS)
- OP FULVESTRANT (INITIAL AND MAINTENANCE)
- OP GDP
- OP GEMCITABINE (EVERY 21 DAYS)
- OP GEMCITABINE (EVERY 28 DAYS)
- OP GEMCITABINE / CISPLATIN (EVERY 21 DAYS) (LUNG)
- OP GEMCITABINE / CISPLATIN (EVERY 21 DAYS) (UROTHELIAL BLADDER)
- OP GEMCITABINE / CISPLATIN (GALLBLADDER)
- OP GEMCITABINE / CISPLATIN (SPLIT DOSE – UROTHELIAL BLADDER)
- OP GEMCITABINE / CISPLATIN / NECITUMUMAB (EVERY 21 DAYS)
- OP GEMCITABINE / DOCETAXEL
- OP GEMCITABINE / VINORELBINE / DOXORUBICIN LIPOSOMAL
- OP GEMCITABINE 1000 (EVERY 7 DAYS)
- OP GEMCITABINE 675
- OP GEMOX (1000/100) EVERY 14 DAYS
- OP GEMOX (675/80)
- OP GEMOX-R (1000/100) EVERY 14 DAYS
- OP IBRITUMOMAB (ZEVALIN Y-90)
- OP IFOSFAMIDE + XRT
- OP INOTUZUMAB OZOGAMICIN CONSOLIDATION
- OP INOTUZUMAB OZOGAMICIN INDUCTION
- OP INTRATHECAL CHEMOTHERAPY
- OP INTRAVESICAL GEMCITABINE / DOCETAXEL PLAN (MONTHLY MAINTENANCE FOR 1 YEAR)
- OP IPILIMUMAB / NIVOLUMAB – MELANOMA
- OP IPILIMUMAB / NIVOLUMAB – NSCLC
- OP IPILIMUMAB / NIVOLUMAB X4 FOLLOWED BY NIVOLUMAB MONOTHERAPY – RENAL CELL CARCINOMA
- OP IRINOTECAN / CETUXIMAB / VEMURAFENIB (EVERY 14 DAYS)
- OP IROX
- OP ISATUXIMAB / CARFILZOMIB / DEXAMETHASONE (IKEMA)
- OP IXABEPILONE
- OP LAPATINIB / CAPECITABINE
- OP LIPOSOMAL DOXORUBICIN (EVERY 14 DAYS)
- OP LIPOSOMAL DOXORUBICIN (EVERY 28 DAYS)
- OP LIPOSOMAL DOXORUBICIN / BEVACIZUMAB
- OP LIPOSOMAL IRINOTECAN / LEUCOVORIN / FLUOROURACIL
- OP LONCASTUXIMAB TESIRINE-LPYL (INITIAL AND MAINTENANCE DOSE)
- OP LOW DOSE CYTARABINE (10 DAYS)
- OP LURBINECTEDIN
- OP MARGETUXIMAB
- OP MFOLFOX6 (EVERY 14 DAYS)
- OP MFOLFOX6 / BEVACIZUMAB (EVERY 14 DAYS)
- OP MFOLFOX6 / CETUXIMAB (EVERY 14 DAYS)
- OP MFOLFOX6 / CETUXIMAB (EVERY 7 DAYS)
- OP MFOLFOX6 / NIVOLUMAB (EVERY 14 DAYS)
- OP MFOLFOX6 / PANITUMUMAB
- OP MFOLFOX6 / ZIV-AFLIBERCEPT (EVERY 14 DAYS)
- OP MINE
- OP MINICHOP
- OP MIRVETUXIMAB SORAVTANSINE-GYNX (EVERY 21 DAYS)
- OP MITOMYCIN (JELMYTO) FOR PYELOCALYCEAL INSTILLATION
- OP MITOXANTRONE / PREDNISONE
- OP MODIFIED CYBORDEX
- OP MODIFIED FOLFIRINOX (EVERY 2 WEEKS) FOR PANCREATIC CANCER (12 CYCLES)
- OP MOGAMULIZUMAB (EVERY 28 DAYS)
- OP MOXETUMOMAB EVERY 28 DAYS
- OP MVAC (DOSE DENSE)
- OP NAB-PACLITAXEL
- OP NAB-PACLITAXEL (EVERY 7 DAYS)
- OP NAB-PACLITAXEL / GEMCITABINE
- OP NAB-PACLITAXEL / GEMCITABINE (DOSE-REDUCED)
- OP NIVOLUMAB (240 MG FLAT DOSE) EVERY 2 WEEKS
- OP NIVOLUMAB (480 MG FLAT DOSE) EVERY 4 WEEKS
- OP NIVOLUMAB AND RELATLIMAB
- OP NIVOLUMAB WEIGHT BASED DOSE (EVERY 14 DAYS)
- OP NON-MODIFIED FOLFIRINOX (EVERY 2 WEEKS)
- OP O-FC
- OP OBINUTUZUMAB
- OP OBINUTUZUMAB (CYCLE 1 ONLY)
- OP OBINUTUZUMAB (CYCLE 2-6)
- OP OBINUTUZUMAB / BENDAMUSTINE FOR CLL EVERY 28 DAYS
- OP OBINUTUZUMAB / BENDAMUSTINE FOR NHL EVERY 28 DAYS
- OP OFATUMUMAB
- OP OFATUMUMAB (EXTENDED TREATMENT)
- OP OFATUMUMAB (REFRACTORY)
- OP PACLITAXEL (DOSE DENSE)
- OP PACLITAXEL / CARBOPLATIN (AUC = 2) EVERY 28 DAYS
- OP PACLITAXEL 80 (EVERY 7 DAYS)
- OP PAD
- OP PANITUMUMAB
- OP PEMBROLIZUMAB (FLAT DOSE)
- OP PEMBROLIZUMAB (WEIGHT-BASED) – MYCOSIS FUNGOIDES/SÉZARY SYNDROME
- OP PEMBROLIZUMAB / CARBOPLATIN / PEMETREXED
- OP PEMBROLIZUMAB / CARBOPLATIN AUC = 5 / FLUOROURACIL CADD EVERY 21 DAYS (HEAD AND NECK)
- OP PEMBROLIZUMAB / PACLITAXEL / CARBOPLATIN (AUC = 5) EVERY 21 DAYS
- OP PEMBROLIZUMAB 400 (EVERY 42 DAYS)
- OP PEMETREXED
- OP PENTOSTATIN
- OP PHESGO (EVERY 21 DAYS)
- OP POLATUZUMAB / BENDAMUSTINE / RITUXIMAB (NHL)
- OP POMP
- OP PRALATREXATE
- OP PRO00036989 CNTY-101 SCREENING PINGALI
- OP PROCARBAZINE / LOMUSTINE / VINCRISTINE
- OP R-CEOP
- OP R-CHOP
- OP R-CVP
- OP R-EPOCH
- OP R-ICE
- OP R-MINICHOP
- OP RAMUCIRUMAB (EVERY 14 DAYS)
- OP RAMUCIRUMAB / DOCETAXEL (EVERY 21 DAYS)
- OP RAMUCIRUMAB / PACLITAXEL (EVERY 28 DAYS)
- OP RESEARCH / HILL H-48389 ALTRUBIO – MULTIPLE DOSE (PK SUBJECTS)
- OP RESEARCH / HILL H-48389 ALTRUBIO – MULTIPLE DOSE (RETREATMENT)
- OP RESEARCH / HILL H-48389 ALTRUBIO – MULTIPLE DOSE PHASE
- OP RESEARCH ALLOVIR / RAMOS KRANCE ALVR106 H-47960 PART A (DOSE ESCALATION)
- OP RESEARCH ALLOVIR / RAMOS KRANCE ALVR106 H-47960 PART A (DOSE ESCALATION) SCREENING
- OP RESEARCH BMT CTN 1703 / 1801 (H-45408) DONOR
- OP RESEARCH BMT CTN 1705 (H-46470)
- OP RESEARCH CTL BESTA H-46862
- OP RESEARCH CTL H-43516 CARMEN
- OP RESEARCH CTL H-43516 CARMEN 6-MONTH FOLLOW UP
- OP RESEARCH CTL H-43516 CARMEN ANNUAL FOLLOW UP
- OP RESEARCH CTL H-43516 CARMEN PROCURMENT
- OP RESEARCH H-42712 MAPSS
- OP RESEARCH H-43405 VISTA FOLLOW UP
- OP RESEARCH H-43405 VISTA INFUSION
- OP RESEARCH H-43405 VISTA PROCUREMENT ORDERS
- OP RESEARCH H-44843 TETRAVI STUDY
- OP RESEARCH H-47739 BAT-IT FOLLOW UP
- OP RESEARCH H-48440 / LULLA ARTEMIS BASELINE
- OP RESEARCH H-48440 / LULLA ARTEMIS FOLLOW UP
- OP RESEARCH H-48440 / LULLA ARTEMIS INFUSION
- OP RESEARCH H-48440 / LULLA ARTEMIS SCREENING
- OP RESEARCH H47561 MSC COVID-19
- OP RESEARCH PRO00020917 CHANG DTP
- OP RESEARCH PRO00020917 DTP ADJUVANT CHANG
- OP RESEARCH PRO00021286 KAMAT NRG-GY009 ARM 1
- OP RESEARCH PRO00021286 KAMAT NRG-GY009 ARM 2
- OP RESEARCH PRO00021286 KAMAT NRG-GY009 ARM 3
- OP RESEARCH PRO00022533 ZHANG ABBVIE M14-239
- OP RESEARCH PRO00023822 / BERNICKER / CANOPY-N ARM 1
- OP RESEARCH PRO00024042 / CHANG CONVERT HR+HER2- BREAST CANCER INTO CBCV ARM 1
- OP RESEARCH PRO00024042 / CHANG CONVERT HR+HER2- BREAST CANCER INTO CBCV ARM 2
- OP RESEARCH PRO00024042 / CHANG CONVERT HR+HER2- BREAST CANCER INTO CBCV ARM 3
- OP RESEARCH PRO00024042 / CHANG CONVERT HR+HER2- BREAST CANCER INTO CBCV ARM 4
- OP RESEARCH PRO00024075 B59 ADJUVANT CONTINUATION NIRAVATH
- OP RESEARCH PRO00024075 B59 NIRAVATH
- OP RESEARCH PRO00024662 NGM 120 STUDY 18-0402 PROTOCOL A3
- OP RESEARCH PRO00024928 BR004 GEYER
- OP RESEARCH PRO00025235 FARACH NRG-GY020
- OP RESEARCH PRO00025653 BERNICKER 4D PHARMA MRX0518-I-002
- OP RESEARCH PRO00026229 ABDELRAHIM NAPOLI-3 ARM 1
- OP RESEARCH PRO00026229 ABDELRAHIM NAPOLI-3 ARM 2
- OP RESEARCH PRO00026637 / KAMAT GOG-3044 (LAE002INT2001) ARM 1
- OP RESEARCH PRO00026637 / KAMAT GOG-3044 (LAE002INT2001) ARM 2
- OP RESEARCH PRO00026826 ML41734 ZHANG
- OP RESEARCH PRO00026860 / SHAH PEVONEDISTAT-2002TAKEDA RANDOMIZED PHASE 2 ARM A
- OP RESEARCH PRO00026860 / SHAH PEVONEDISTAT-2002TAKEDA VENETOCLAX PLUS AZACITIDINE RANDOMIZED PHASE 2 ARM B
- OP RESEARCH PRO00026882 JAIN A221602
- OP RESEARCH PRO00028602/INTEGRAL NON-RESPONDERS
- OP RESEARCH PRO00028602/INTEGRAL RESPONDERS
- OP RESEARCH PRO00028925 FULVESTRANT PLUS ABEMACICLIB WITH FULVESTRANT RUN-IN CHANG
- OP RESEARCH PRO00028925 FULVESTRANT PLUS ABEMACICLIB WITHOUT FULVESTRANT RUN-IN CHANG
- OP RESEARCH PRO00029142 / SATKUNASIVAM ENFORTUMAB VEDOTIN PEMBROLIZUMAB (MK-3475) PHASE 3 ADJUVANT ARM A
- OP RESEARCH PRO00029142 / SATKUNASIVAM ENFORTUMAB VEDOTIN PEMBROLIZUMAB (MK-3475) PHASE 3 NEOADJUVANT ARM A
- OP RESEARCH PRO00029142 / SATKUNASIVAM GEMCITABINE + CISPLATIN PHASE 3 NEOADJUVANT ARM B
- OP RESEARCH PRO00029646 / NIRAVATH OLEMA OP-1250-001 PHASE II MONOTHERAPY STUDY IN ADULTS WITH ADVANCED OR METASTATIC (HR)-POSITIVE, HER2-NEGATIVE BREAST CANCER (SCREENING)
- OP RESEARCH PRO00029646 / NIRAVATH OLEMA OP-1250-001 PHASE II MONOTHERAPY STUDY IN ADULTS WITH ADVANCED OR METASTATIC (HR)-POSITIVE, HER2-NEGATIVE BREAST CANCER (TREATMENT)
- OP RESEARCH PRO00029661 A081801 ZHANG ARM A CHOICE 1
- OP RESEARCH PRO00029661 A081801 ZHANG ARM A CHOICE 2
- OP RESEARCH PRO00029661 A081801 ZHANG ARM A CHOICE 3
- OP RESEARCH PRO00029661 A081801 ZHANG ARM A CHOICE 4
- OP RESEARCH PRO00029661 A081801 ZHANG ARM B CHOICE 1
- OP RESEARCH PRO00029661 A081801 ZHANG ARM B CHOICE 2
- OP RESEARCH PRO00029661 A081801 ZHANG ARM B CHOICE 3
- OP RESEARCH PRO00029661 A081801 ZHANG ARM B CHOICE 4
- OP RESEARCH PRO00029661 A081801 ZHANG ARM C CHOICE 1
- OP RESEARCH PRO00029661 A081801 ZHANG ARM C CHOICE 2
- OP RESEARCH PRO00029661 A081801 ZHANG ARM C CHOICE 3
- OP RESEARCH PRO00029661 A081801 ZHANG ARM C CHOICE 4
- OP RESEARCH PRO00029685 A011801 JAIN
- OP RESEARCH PRO00030489 HMCC-BR22-001 BASELINE ASSESSMENTS NIRAVATH
- OP RESEARCH PRO00030489 HMCC-BR22-001 NIRAVATH
- OP RESEARCH PRO00030489 HMCC-BR22-001 SCREENING ASSESSMENTS NIRAVATH
- OP RESEARCH PRO00031037 NCT04513717 ARM 1 HAQUE
- OP RESEARCH PRO00031037 NCT04513717 ARM 2 HAQUE
- OP RESEARCH PRO00031037 NCT04513717 ARM 3 HAQUE
- OP RESEARCH PRO00031037 NCT04513717 ARM 4 HAQUE
- OP RESEARCH PRO00031234 / ABDELRAHIM TAS-120-202 COHORT A & B
- OP RESEARCH PRO00031234 / ABDELRAHIM TAS-120-202 COHORT A & B SCREENING
- OP RESEARCH PRO00031234 / ABDELRAHIM TAS-120-202 COHORT C
- OP RESEARCH PRO00031234 / ABDELRAHIM TAS-120-202 COHORT C SCREENING
- OP RESEARCH PRO00031953 NRG-GY023 SINGH ARM 1 REGIMEN 1
- OP RESEARCH PRO00031953 NRG-GY023 SINGH ARM 1 REGIMEN 2
- OP RESEARCH PRO00031953 NRG-GY023 SINGH ARM 1 REGIMEN 3 DAILY TOPOTECAN
- OP RESEARCH PRO00031953 NRG-GY023 SINGH ARM 1 REGIMEN 3 WEEKLY TOPOTECAN
- OP RESEARCH PRO00031953 NRG-GY023 SINGH ARM 2
- OP RESEARCH PRO00031953 NRG-GY023 SINGH ARM 3
- OP RESEARCH PRO00031953 NRG-GY023 SINGH ARM 4
- OP RESEARCH PRO00032239 ML43352 ABDELRAHIM
- OP RESEARCH PRO00032606 LOXO-BTK-20022 ARM A SHAH
- OP RESEARCH PRO00032606 LOXO-BTK-20022 ARM B SHAH
- OP RESEARCH PRO00032606 LOXO-BTK-20022 SHAH ARM A BASELINE SCREENING
- OP RESEARCH PRO00032606 LOXO-BTK-20022 SHAH ARM B BASELINE SCREENING
- OP RESEARCH PRO00032923 NCT04935359 ABDELRAHIM
- OP RESEARCH PRO00033015 ONC-392-001 CHANG
- OP RESEARCH PRO00033015 ONC-392-001 SCREENING CHANG
- OP RESEARCH PRO00033043 CTO53-MM-02 (LUMMICAR STUDY 2) FOLLOW UP FOR EARLY WITHDRAWAL GANGULY
- OP RESEARCH PRO00033043 CTO53-MM-02 (LUMMICAR STUDY 2) GANGULY
- OP RESEARCH PRO00034040 / ZAID MERCK MK-7684A-005-03 COHORT A1 ARM 1
- OP RESEARCH PRO00034040 / ZAID MERCK MK-7684A-005-03 COHORT A1 ARM 2
- OP RESEARCH PRO00034040 / ZAID MERCK MK-7684A-005-03 COHORT A2 ARM 1
- OP RESEARCH PRO00034040 / ZAID MERCK MK-7684A-005-03 COHORT B1 ARM 1
- OP RESEARCH PRO00034040 MERCK MK-7648A-005-03 COHORT I / ARM 8 (DOCETAXEL 75 MG PER M2)
- OP RESEARCH PRO00034040 MERCK MK-7648A-005-03 COHORT I / ARM 8 (TAXOL 175 MG PER M2)
- OP RESEARCH PRO00034040 MERCK MK-7648A-005-03 COHORT I / ARM 8 (TAXOL 60 MG PER M2)
- OP RESEARCH PRO00034040 MERCK MK-7648A-005-03 COHORT I / ARM 8 (TAXOL 80 MG PER M2)
- OP RESEARCH PRO00035089 / EFSTATHIOU XL184-315 RANDOMIZED PHASE 3 ABIRATERONE WITH PREDNISONE NHT CONTROL ARM
- OP RESEARCH PRO00035089 / EFSTATHIOU XL184-315 RANDOMIZED PHASE 3 CABOZANTINIB WITH ATEZOLIZUMAB EXPERIMENTAL ARM
- OP RESEARCH PRO00035089 / EFSTATHIOU XL184-315 RANDOMIZED PHASE 3 ENZALUTAMIDE NHT CONTROL ARM
- OP RESEARCH PRO00035089 / EFSTATHIOU XL184-315 RANDOMIZED PHASE 3 SAFETY EVALUATION VISITS
- OP RESEARCH PRO00035089 / EFSTATHIOU XL184-315 RANDOMIZED PHASE 3 SCREENING
- OP RESEARCH PRO00035094 / SHAH NS-018-201 NS PHARMA PHASE 2B RANDOMIZED, CONTROLLED 2-ARM STUDY ARM A
- OP RESEARCH PRO00035094 / SHAH NS-018-201 NS PHARMA PHASE 2B RANDOMIZED, CONTROLLED 2-ARM STUDY BAT ARM B
- OP RESEARCH PRO00035094 / SHAH NS-018-201 NS PHARMA PHASE 2B RANDOMIZED, CONTROLLED 2-ARM STUDY SCREENING
- OP RESEARCH PRO00035654 NCT04071457 GANGULY ARM 1A STEP 3
- OP RESEARCH PRO00035654 NCT04071457 GANGULY ARM 2A STEP 3
- OP RESEARCH PRO00035654 NCT04071457 GANGULY PRE REGISTRATION STEP 1
- OP RESEARCH PRO00035655 / GANGULY EAA173 DARATUMUMAB-HYALURONIDASE SC + LENALIDOMIDE + DEXAMETHASONE ARM A
- OP RESEARCH PRO00035655 / GANGULY EAA173 DARATUMUMAB-HYALURONIDASE SC + LENALIDOMIDE + DEXAMETHASONE SCREENING
- OP RESEARCH PRO00035655 / GANGULY EAA173 LENALIDOMIDE + DEXAMETHASONE ARM B
- OP RESEARCH PRO00035735 ANHL1931 PINGALI ARM C / E
- OP RESEARCH PRO00035735 ANHL1931 PINGALI ARM D / F
- OP RESEARCH PRO00035735 ANHL1931 SCREENING PINGALI
- OP RESEARCH PRO00035972 / ZHANG ALX ONCOLOGY PEMBROLIZUMAB ARM 1
- OP RESEARCH PRO00035972 / ZHANG ALX ONCOLOGY PEMBROLIZUMAB ARM 2
- OP RESEARCH PRO00035972 / ZHANG ALX ONCOLOGY PEMBROLIZUMAB SAFETY LEAD IN
- OP RESEARCH PRO00035972 / ZHANG ALX ONCOLOGY SCREENING
- OP RESEARCH PRO00035973 NCT04675333 ARM 1 ZHANG
- OP RESEARCH PRO00035973 NCT04675333 ARM 2 ZHANG
- OP RESEARCH PRO00035973 NCT04675333 LEAD IN ZHANG
- OP RESEARCH PRO00035973 NCT04675333 SCREENING ZHANG
- OP RESEARCH PRO00035985 EA9181 NCT04530565 MAINTENANCE SHAH
- OP RESEARCH PRO00035985 EA9181 NCT04530565 PRIOR TO ALLOGENIC HCT
- OP RESEARCH PRO00035985 EA9181 NCT04530565 STEP 0 PRE-REGISTRATION SHAH
- OP RESEARCH PRO00035985 EA9181 NCT04530565 STEP 1 REGISTRATION (PRE-INDUCTION) / ARM A / STEP 2 RANDOMIZATION SHAH
- OP RESEARCH PRO00035985 EA9181 NCT04530565 STEP 3 PRE-REGISTRATION SHAH
- OP RESEARCH PRO00036193 ARM A MMY3002 GANGULY
- OP RESEARCH PRO00036193 ARM B MMY3002 GANGULY
- OP RESEARCH PRO00036193 ARM C MMY3002 GANGULY
- OP RESEARCH PRO00036193 MMY3002 SCREENING GANGULY
- OP RESEARCH PRO00036218 BAYER 21516 EFSTATHIOU
- OP RESEARCH PRO00036218 BAYER 21516 SCREENING / BASELINE EFSTATHIOU
- OP RESEARCH PRO00036219 / EFSTATHIOU I3Y-MC-JPEG CYCLONE 3 PHASE 3 EXPERIMENTAL ARM ABEMACICLIB ( LY2835219) + ABIRATERONE + PREDNISONE / CONTROL ARM PLACEBO + ABIRATERONE + PREDNISONE
- OP RESEARCH PRO00036219 / EFSTATHIOU I3Y-MC-JPEG CYCLONE 3 PHASE 3 SCREENING
- OP RESEARCH PRO00036449 / RAMSHESH NRG-BR007 ENDOCRINE THERAPY + RT PHASE III ARM 1
- OP RESEARCH PRO00036449 / RAMSHESH NRG-BR007 ENDOCRINE THERAPY ONLY PHASE III ARM 2
- OP RESEARCH PRO00036449 / RAMSHESH NRG-BR007 PHASE III SCREENING
- OP RESEARCH PRO00036844 / EFSTATHIOU AZD5305 WITH ABIRATERONE ACETATE OPEN LABEL PHASE I/IIA PETRANHA ARM 2
- OP RESEARCH PRO00036844 / EFSTATHIOU AZD5305 WITH DAROLUTAMIDE OPEN LABEL PHASE I/IIA PETRANHA ARM 3
- OP RESEARCH PRO00036844 / EFSTATHIOU AZD5305 WITH ENZALUTAMIDE OPEN LABEL PHASE I/IIA PETRANHA ARM 1
- OP RESEARCH PRO00036844 / EFSTATHIOU AZD5305 WITH HORMONAL AGENTS OPEN LABEL PHASE I/IIA PETRANHA SCREENING
- OP RESEARCH PRO00036985 NCT05132504 POST-SURGERY ESNAOLA
- OP RESEARCH PRO00036985 NCT05132504 PRE-SURGERY ESNAOLA
- OP RESEARCH PRO00036985 NCT05132504 SCREEING ESNAOLA
- OP RESEARCH PRO00037014 / SHAH BMS CA055-026 AZACITIDINE RANDOMIZED SCREENING
- OP RESEARCH PRO00037014 / SHAH BMS CA055-026 RANDOMIZED AZACITIDINE
- OP RESEARCH PRO00037014 / SHAH BMS CA055-026 RANDOMIZED AZACITIDINE EXTENSION PHASE
- OP RESEARCH PRO00037085 D926XC00001 ARM 1 MAI
- OP RESEARCH PRO00037085 D926XC00001 ARM 2 MAI
- OP RESEARCH PRO00037085 D926XC00001 ARM 3 MAI
- OP RESEARCH PRO00037085 D926XC00001 SCREENING MAI
- OP RESEARCH PRO00037462 ADM00022216 PHASE 1 PART B ZHANG
- OP RESEARCH PRO00037489 / SATKUNASIVAM PEMBROLIZUMAB (MK-3475) AND PEMBROLIZUMAB FOR NMIBC UNRESPONSIVE TO BCG PHASE II COHORT C ARM 1
- OP RESEARCH PRO00037489 / SATKUNASIVAM PEMBROLIZUMAB (MK-3475) AND PEMBROLIZUMAB FOR NMIBC UNRESPONSIVE TO BCG PHASE II COHORT C ARM 2
- OP RESEARCH PRO00037521 NCT05609968 MK-3475 ARM 1 ZHANG
- OP RESEARCH PRO00037521 NCT05609968 MK-3475 ARM 2 ZHANG
- OP RESEARCH PRO00037521 NCT05609968 MK-3475 SCREENING ZHANG
- OP RESEARCH PRO00037588 IOV-GM1-201 BASELINE GANGULY
- OP RESEARCH PRO00037588 IOV-GM1-201 FUP / EOA / LTFU / EOA GANGULY
- OP RESEARCH PRO00037588 IOV-GM1-201 SCREENING GANGULY
- OP RESEARCH PRO00037588 IOV-GM1-201 TUMOR HARVEST GANGULY
- OP RESEARCH PRO00037627 / GANGULY P-BCMA-ALL01 OPEN-LABEL, PHASE I SCREENING AND BASELINE
- OP RESEARCH PRO00037679 / ZHANG EA5182 FOR PATIENTS WITH METASTATIC EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) RANDOMIZED SCREENING
- OP RESEARCH PRO00037679 / ZHANG EA5182 OSIMERTINIB (AZD9291) FOR PATIENTS WITH METASTATIC EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) RANDOMIZED ARM A
- OP RESEARCH PRO00037679 / ZHANG EA5182 OSIMERTINIB (AZD9291) WITH BEVACIZUMAB FOR PATIENTS WITH METASTATIC EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) RANDOMIZED ARM B
- OP RESEARCH PRO00037682 S2302 SWOG ARM B
- OP RESEARCH PRO00037682 S2302 SWOG SCREENING BASELINE
- OP RESEARCH PRO00037739 / SHAH CABL001AUS08 PHASE II FOR CHRONIC MYELOGENOUS LEUKEMIA (ASC2ESCALATE)
- OP RESEARCH PRO00037739 / SHAH CABL001AUS08 PHASE II FOR CHRONIC MYELOGENOUS LEUKEMIA (ASC2ESCALATE) SCREENING
- OP RESEARCH PRO00037808 D361DC00001 SUN ARM A
- OP RESEARCH PRO00037808 D361DC00001 SUN ARM B
- OP RESEARCH PRO00037808 D361DC00001 SUN SCREENING
- OP RESEARCH PRO00037831 ML44719 ABDELRAHIM ARM A
- OP RESEARCH PRO00037831 ML44719 ABDELRAHIM ARM B
- OP RESEARCH PRO00037831 ML44719 ABDELRAHIM SCREENING
- OP RESEARCH PRO00037834 IDE196-002 / IND 143026 MAQSOOD PHASE 2A ARM 1
- OP RESEARCH PRO00037834 IDE196-002 / IND 143026 MAQSOOD PHASE 2A ARM 2
- OP RESEARCH PRO00037834 IDE196-002 / IND 143026 MAQSOOD PHASE 2A CHEMOTHERAPY ARM 3 COMPARATOR ARM
- OP RESEARCH PRO00037834 IDE196-002 / IND 143026 MAQSOOD PHASE 2B AND 3 CHEMOTHERAPY ARM 2 COMPARATOR ARM
- OP RESEARCH PRO00037834 IDE196-002 / IND 143026 MAQSOOD SCREENING
- OP RESEARCH PRO00037922 / GANGULY PFIZER C1071032 ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPD) ARM B
- OP RESEARCH PRO00037922 / GANGULY PFIZER C1071032 OPEN-LABEL SCREENING
- OP RESEARCH PRO00037933 / MERCK MK-2870-005/GOG-3095 ARM 1
- OP RESEARCH PRO00037933 / MERCK MK-2870-005/GOG-3095 ARM 2 DOXORUBICIN
- OP RESEARCH PRO00037933 / MERCK MK-2870-005/GOG-3095 ARM 2 PACLITAXEL
- OP RESERACH PRO00025711 / HEYNE / CA2099DW BMS ARM A
- OP RESERACH PRO00025711 / HEYNE / CA2099DW BMS ARM B
- OP RITUXIMAB (WEEKLY X4)
- OP RITUXIMAB / BORTEZOMIB
- OP RITUXIMAB 375
- OP RITUXIMAB 375 MAINTENANCE
- OP RITUXIMAB 500
- OP RITUXIMAB INTRATHECAL/INTRAOMMAYA
- OP ROMIDEPSIN
- OP RSH GO42784 (NASBP B-61) GIREDESTRANT/JAIN ARM A
- OP RSH GO42784 (NASBP B-61) GIREDESTRANT/JAIN ARM B
- OP RSH GO42784 (NASBP B-61) GIREDESTRANT/JAIN SCREENING
- OP RSH PRO00026304 INFORM STUDY ABDELRAHIM
- OP RSH PRO00029151 / CMP-001-007 ZHANG ARM A
- OP RSH PRO00036001 / CA057-008 ARM A / CC-92480- CARFILZOMIB- DEXAMETHASONE
- OP RSH PRO00036001 / CA057-008 ARM B OPTION 1 / CARFILZOMIB- DEXAMETHASONE
- OP RSH PRO00036001 / CA057-008 ARM B OPTION 2 / CARFILZOMIB- DEXAMETHASONE
- OP RSH PRO00036001 / CA057-008 SCREENING
- OP RSH PRO00036343 / IMCGP100-203 / ARM C
- OP RSH PRO00036354 SHILPAN LOXO-BTK-20030 SCREENING
- OP RSH PRO00036423 / TT420C1206 ORAL CHEMO
- OP RSH PRO00036423 / TT420C1206 SCREENING
- OP RSH PRO00036451 NAIR ML43171 GIREDESTRANT CONTROL ARM B
- OP RSH PRO00036451 NAIR ML43171 GIREDESTRANT EXPERIMENTAL ARM A
- OP RSH PRO00036451 NAIR ML43171 GIREDESTRANT SCREENING
- OP RSH PRO00037447 BN22-001 SBRT TEH SCREENING
- OP RSH PRO00037447 BN22-001 SBRT TEH TREATMENT ARM
- OP RSH PRO00037490 / ARM A – TAR-200 DEVICE + IV CETRELIMAB
- OP RSH PRO00037694 ALLIANCE A012103 – JAIN ARM 1 Q 42 DAYS
- OP RSH PRO00037694 ALLIANCE A012103 – JAIN ARM 1 Q21 DAYS
- OP RSH PRO00037694 ALLIANCE A012103 – JAIN ARM 2 OBSERVATION
- OP RSH PRO00037694 ALLIANCE A012103 – JAIN SCREENING
- OP RSH PRO00037695 / HN009 / ARM 1 AND 3
- OP RSH PRO00037695 / HN009 / ARM 2 AND 4
- OP RSH PRO00037695 / HN009 / BASELINE / SCREENING
- OP RSH PRO00037748 ABDELRAHIM CO44668 BOTH ARMS
- OP RSH PRO00037748 ABDELRAHIM CO44668 SCREENING
- OP SACITUZUMAB GOVITECAN-HZIY
- OP SALTZ
- OP SIPULEUCEL-T (PROVENGE) EVERY 14 DAYS
- OP TAC
- OP TAFASITAMAB-CXIX
- OP TAP
- OP TC
- OP TCH (LOADING AND MAINTENANCE REGIMEN)
- OP TCH (LOADING DOSE ONLY)
- OP TCH (MAINTENANCE REGIMEN)
- OP TECLISTAMAB-CQYV (MAINTENANCE)
- OP TEMSIROLIMUS (WEEKLY)
- OP TFOX (EVERY 2 WEEKS)
- OP TISOTUMAB VEDOTIN-TFTV EVERY 21 DAYS
- OP TOPOTECAN (DAILY)
- OP TOPOTECAN (EVERY 7 DAYS)
- OP TOPOTECAN (WEEKLY)
- OP TOPOTECAN / BEVACIZUMAB
- OP TOPOTECAN / BEVACIZUMAB (EVERY 7 DAYS)
- OP TRABECTEDIN 1.1 MG PER M2 (NO AMBULATORY PUMP)
- OP TRABECTEDIN 1.5 MG PER M2 (AMBULATORY PUMP)
- OP TRASTUZUMAB (EVERY 21 DAYS) / PACLITAXEL (EVERY 7 DAYS) – TRASTUZUMAB MAINTENANCE (APT TRIAL)
- OP TRASTUZUMAB (EVERY 21 DAYS) LOADING AND MAINTENANCE DOSE
- OP TRASTUZUMAB (EVERY 21 DAYS) LOADING DOSE ONLY
- OP TRASTUZUMAB (EVERY 21 DAYS) MAINTENANCE DOSE
- OP TRASTUZUMAB (EVERY 7 DAYS)
- OP TRASTUZUMAB / CAPECITABINE (CYCLE 1 ONLY)
- OP TRASTUZUMAB / CAPECITABINE (CYCLE 2 AND BEYOND)
- OP TRASTUZUMAB / CAPECITABINE (LOADING AND MAINTENANCE REGIMEN)
- OP TRASTUZUMAB / LAPATINIB (CYCLE 1 ONLY)
- OP TRASTUZUMAB / LAPATINIB (CYCLE 2 AND BEYOND-WEEKLY)
- OP TRASTUZUMAB / LAPATINIB (LOADING AND MAINTENANCE REGIMEN)
- OP TRASTUZUMAB / OXALIPLATIN / LEUCOVORIN / FLUOROURACIL
- OP TRASTUZUMAB / PACLITAXEL (EVERY 7 DAYS)
- OP TRASTUZUMAB / PERTUZUMAB (EVERY 21 DAYS) LOADING AND MAINTENANCE DOSE
- OP TRASTUZUMAB / PERTUZUMAB / DOCETAXEL (CYCLE 1 AND CYCLE 2-4)
- OP TRASTUZUMAB / PERTUZUMAB / DOCETAXEL (CYCLE 1 ONLY)
- OP TRASTUZUMAB / PERTUZUMAB / DOCETAXEL (CYCLE 2 AND BEYOND)
- OP TRASTUZUMAB / PERTUZUMAB / DOCETAXEL / CARBOPLATIN (LOADING AND MAINTENANCE REGIMEN)
- OP TRASTUZUMAB / PERTUZUMAB / DOCETAXEL / CARBOPLATIN (LOADING DOSE ONLY)
- OP TRASTUZUMAB / PERTUZUMAB / DOCETAXEL / CARBOPLATIN (MAINTENANCE REGIMEN)
- OP TRASTUZUMAB / PERTUZUMAB / PACLITAXEL (CYCLE 1 AND CYCLE 2-6)
- OP TRASTUZUMAB / PERTUZUMAB / PACLITAXEL (CYCLE 1 ONLY)
- OP TRASTUZUMAB / PERTUZUMAB / PACLITAXEL (CYCLE 2 TO 6)
- OP TRASTUZUMAB AND HYALURONIDASE (EVERY 21 DAYS) MAINTENANCE
- OP TREMELIMUMAB ONCE / DURVALUMAB (FLAT DOSE 1500 MG) EVERY 28 DAYS – UNRESECTABLE HEPATOCELLULAR CARCINOMA
- OP TVEC
- OP VDC
- OP VINCRISTINE
- OP VINORELBINE (EVERY 7 DAYS)
- OP VIP
- OP XELIRI (EVERY 21 DAYS)
- OP XELIRI / BEVACIZUMAB (EVERY 14 DAYS)
- OP XELIRI / CETUXIMAB (EVERY 14 DAYS)
- OP XELIRI / CETUXIMAB (EVERY 7 DAYS)
- OP XELIRI / PANITUMUMAB (EVERY 7 DAYS)
- OP XELIRI / ZIV-AFLIBERCEPT (EVERY 21 DAYS)
- OP XELOX (EVERY 21 DAYS)
- OP XELOX / BEVACIZUMAB (EVERY 14 DAYS)
- OP XELOX / BEVACIZUMAB (EVERY 21 DAYS)
- OP XELOX / CETUXIMAB
- OP XELOX / CETUXIMAB (EVERY 14 DAYS)
- OP XELOX / PANITUMUMAB
- OP XELOX / ZIV-AFLIBERCEPT (EVERY 14 DAYS)
- OP/IP CAGT CYCLOPHOSPHAMIDE / FLUDARABINE / BREXUCABTAGENE AUTOLEUCEL
- OP/IP CAGT CYCLOPHOSPHAMIDE / FLUDARABINE / IDECABTAGENE VICLEUCEL
- OP/IP CAGT CYCLOPHOSPHAMIDE / FLUDARABINE / LISOCABTAGENE MARALEUCEL
- OP/IP EP-EMA
- OP/IP EPCORITAMAB-BYSP
- OP/IP PRO00036989 SCHEDULE A CNTY-101 PINGALI
- OP/IP PRO00036989 SCHEDULE B CNTY-101 PINGALI
- OP/IP RESEARCH BMT CTN 1703 / 1801 (H-45408) PATIENT
- OP/IP RESEARCH CTL H-43516 CARMEN
- RESARCH PRO17492 DARCOURT – PHASE 1B TRIAL OF L-NMMA IN COMBINATION WITH PEMBROLIZUMAB
- RESEARCH / HILL CTL H-43761 CRIMSON-NE
- RESEARCH / HILL CTL H-43761 CRIMSON-NE FOLLOW-UP
- RESEARCH / HILL CTL H-43761 CRIMSON-NE PROCUREMENT ORDERS
- RESEARCH CATCH H-49796/ARMAGHANY
- RESEARCH CTL GENERIC BLOOD COLLECTION ORDERS
- RESEARCH CTL GENERIC INFUSION ORDERS
- RESEARCH CTL H-23574 CHARKALL
- RESEARCH CTL H-23574 CHARKALL FOLLOW-UP LABS OP
- RESEARCH CTL H-24489 AHMED HEROS
- RESEARCH CTL H-27471 CARRUM TACTAL
- RESEARCH CTL H-29617 GRALE
- RESEARCH CTL H-29966 HESLOP ARMS
- RESEARCH CTL H-29966 HESLOP ARMS FOLLOW-UP LABS
- RESEARCH CTL H-31970 SAGAN
- RESEARCH CTL H-31973 AH MED ICAR
- RESEARCH CTL H-31973 AH MED ICAR FOLLOW-UP LABS OP
- RESEARCH CTL H-32335 WANG VEGAS
- RESEARCH CTL H-33133 RAMOS CARPASCIO
- RESEARCH CTL H-33900 HESLOP CITADEL
- RESEARCH CTL H-33903 CHARMS
- RESEARCH CTL H-33903 CHARMS FOLLOW-UP LABS
- RESEARCH CTL H-35101 NAIK BELLICUM BP-004U
- RESEARCH CTL H-35136 RAMOS VIRALYM A
- RESEARCH CTL H-35253 ROUCE MABEL
- RESEARCH CTL H-35253 ROUCE MABEL FOLLOW-UP LABS
- RESEARCH CTL H-35253 ROUCE MABEL T-CELL INFUSION ONLY
- RESEARCH CTL H-35425 HESLOP TACTASOM
- RESEARCH CTL H-35626 LULLA TACTAM
- RESEARCH CTL H-35885 NAIK VIRALYM B
- RESEARCH CTL H-35885 NAIK VIRALYM B FOLLOW-UP LABS
- RESEARCH CTL H-35887 OMER VIRALYM C
- RESEARCH CTL H-35887 OMER VIRALYM C FOLLOW-UP LABS
- RESEARCH CTL H-36021 HESTIA
- RESEARCH CTL H-36346 CARRUM ADSPAM
- RESEARCH CTL H-37042 LULLA STELLA
- RESEARCH CTL H-37966 RELY-30
- RESEARCH CTL H-37966 RELY-30 FOLLOW-UP LABS OP
- RESEARCH CTL H-37966 RELY-30 INITIAL PROCUREMENT ORDERS
- RESEARCH CTL H-37966 RELY-30 SECOND PROCUREMENT ORDERS
- RESEARCH CTL H-39090 PREVALE
- RESEARCH CTL H-39090 PREVALE FOLLOW-UP LABS OP
- RESEARCH CTL H-39209 (TACTIC) ADULT
- RESEARCH CTL H-39209 (TACTIC) PROCUREMENT ORDERS
- RESEARCH CTL H-40378 (TACTOPS)
- RESEARCH CTL H-40378 (TACTOPS) PROCUREMENT ORDERS
- RESEARCH CTL H-40466 MAGENTA
- RESEARCH CTL H-40466 MAGENTA FOLLOW-UP LABS OP
- RESEARCH CTL H-44526 ANCHOR
- RESEARCH CTL H-46604 BESTA DONOR PROCUREMENT
- RESEARCH GAIL-N FOLLOW-UP LABS
- RESEARCH GAIL-N PHASE I
- RESEARCH GAIL-N T-CELL INFUSION ONLY
- RESEARCH H-45118- DONOR PROCUREMENT FOR THIRD PARTY MULTIVIRUS SPECIFIC T CELL LINES
- RESEARCH LAPACT PRO00013022 ABI-007-PANC-007 LEHANE ARM A POST-INDUCTION ABRAXANE + GEMCITABINE D1,8,15 UNTIL DISEASE PROGRESSION (AUGUST 27, 2014)
- RESEARCH LAPACT PRO00013022 ABI-007-PANC-007 LEHANE INDUCTION ABRAXANE + GEMCITABINE D1,8,15 (AUGUST 27, 2014)
- RESEARCH LULLA GLYCAR H-38942
- RESEARCH PRO000022921 / SATKUNASIVAM CA2099 NIVOLUMAB OR NIVOLUMAB/BMS-986205 PHASE 2 ARM A RANDOMIZED
- RESEARCH PRO000022921 / SATKUNASIVAM CA2099 NIVOLUMAB OR NIVOLUMAB/BMS-986205 PHASE 2 ARM B RANDOMIZED
- RESEARCH PRO000022921 / SATKUNASIVAM CA2099 NIVOLUMAB OR NIVOLUMAB/BMS-986205 PHASE 2 ARM C RANDOMIZED
- RESEARCH PRO00005852 RTOG 0724/GOG-0724 – ARM 1 – KAMAT CONCURRENT WEEKLY CISPLATIN + RAIDATION + BRACHYTHERAPY
- RESEARCH PRO00005852 RTOG 0724/GOG-0724 – ARM 2 KAMAT CONCURRENT WEEKLY CISPLATIN + RT + BRACHY WITH PACLITAXEL +CARBOPLATIN 4CYCLES
- RESEARCH PRO00008985 CHANG-BO27938 ARM B_(VERSION 5: 07-09-2014)
- RESEARCH PRO00009452 BERNICKER-GALAXY 2 TRIAL ARM A (12-19-2014)
- RESEARCH PRO00010074 CHANG-TEAL ARM 2 (VERSION 5: 02-06-2015)
- RESEARCH PRO00010459 PACRITINIB 200MG BID – IYER (AMENDMENT 2: 7-31-2014)
- RESEARCH PRO00010459 PACRITINIB 400MG DAILY – IYER (AMENDMENT 2: -7-31-2014)
- RESEARCH PRO00010820 BERNICKER ABI-007-NSCL-003 INDUCTION (10-28-2014)
- RESEARCH PRO00010820 BERNICKER ABI-007-NSCL-003 MAINTENANCE (10-28-2014)
- RESEARCH PRO00011277 GOG-0286B KAMAT PACLITAXEL / CARBOPLATIN EVERY 21 D + METFORMIN/PLACEBO DAILY (3-10-15)
- RESEARCH PRO00011685 NIRAVATH L-NMMA PLUS DOCETAXEL
- RESEARCH PRO00011897 NRG-LU001 CONCURRENT CHEMOTHERAPY + RADIATION ARM A PACLITAXEL 50 MG/M2 / CARBOPLATIN AUC 2 – WEEKLY FOR 6 CYCLES (VERSION 5-7-15)
- RESEARCH PRO00012194 CHANG-EGF117165 ARM B TRASTUZUMAB + NAB-PACLITAXEL (03-26-2014)
- RESEARCH PRO00012194 CHANG-EGF117165 ARM B TRASTUZUMAB + PACLITAXEL (03-26-2014)
- RESEARCH PRO00012803 GOG0281 KAMAT ARM A LETROZOLE 2.5 (VERSION 9: 08-22-2016)
- RESEARCH PRO00012803 GOG0281 KAMAT ARM A PACLITAXEL 80 (EVERY 7 DAYS) (VERSION 9: 08-22-2016)
- RESEARCH PRO00012803 GOG0281 KAMAT ARM A PEGYLATED LIPOSOMAL DOXORUBICIN 40 (VERSION 9: 08-22-2016)
- RESEARCH PRO00012803 GOG0281 KAMAT ARM A PEGYLATED LIPOSOMAL DOXORUBICIN 50 (VERSION 9: 08-22-2016)
- RESEARCH PRO00012803 GOG0281 KAMAT ARM A TAMOXIFEN 20 (VERSION 9: 08-22-2016)
- RESEARCH PRO00012803 GOG0281 KAMAT ARM A TOPOTECAN 4 (VERSION 9: 08-22-2016)
- RESEARCH PRO00013139 GOG3005 KAMAT ARMS 1, 2, 3 CARBOPLATIN + PACLITAXEL Q3 WEEKS + PLACEBO/VELIPARIB FOLLOWED BY PLACEBO/VELIPARIB MAINTENANCE THERAPY
- RESEARCH PRO00013139 GOG3005 KAMAT ARMS 1, 2, 3 CARBOPLATIN + PACLITAXEL WEEKLY + PLACEBO/VELIPARIB FOLLOWED BY PLACEBO/VELIPARIB MAINTENANCE THERAPY
- RESEARCH PRO00013982 MERCK KEYNOTE-100 DARCOURT – COHORTS A AND B – PEMBROLIZUMAB
- RESEARCH PRO00014219 BASKIN BEVACIZUMAB (SOC ARM)
- RESEARCH PRO00014219 BASKIN LOMUSTINE (SOC ARM)
- RESEARCH PRO00014219 BASKIN METRONOMIC TEMOZOLOMIDE DAILY X 28 (SOC ARM)
- RESEARCH PRO00014219 BASKIN TEMOZOLOMIDE (SOC ARM)
- RESEARCH PRO00014219 BASKIN TOCAGEN (TOCA 511-15-01) EXPERIMENTAL ARM
- RESEARCH PRO00014976 ENSIGN BERNICKER (VERSION 7: 11-13-2017)
- RESEARCH PRO00015001 TAK-659
- RESEARCH PRO00015047 INCB-57643 IYER
- RESEARCH PRO00015423 INCB39110-206 IYER
- RESEARCH PRO00015851 NU15B08 CHANG (VERSION 3: 01-11-2017)
- RESEARCH PRO00016419 / BERNICKER EA5142 (ADJUVANT NIVOLUMAB)
- RESEARCH PRO00017710 NIRAVATH REVIVE ARM 1 VAGINAL ESTROGEN ARM
- RESEARCH PRO00017710 NIRAVATH REVIVE ARM 2: REPLENS ARM
- RESEARCH PRO00019188 RANDHAWA / CALB001A2301
- RESEARCH PRO00019585 DARCOURT / BAY 1163877 (CONTROL ARM DOCETAXEL 75 MG/M2 ONCE EVERY 21 DAYS)
- RESEARCH PRO00019585 DARCOURT / BAY 1163877 (CONTROL ARM PACLITAXEL 175 MG/M2 ONCE EVERY 21 DAYS)
- RESEARCH PRO00019585 DARCOURT / BAY 1163877 (RANDOMIZED TO ROGARATINIB IN CYCLE 1)
- RESEARCH PRO00019601 ABDELRAHIM / IPSEN: MM-398-07-02-03
- RESEARCH PRO00019886 / BERNICKER M16-298 MERU (RANDOMIZED TO ROVALPITUZUMAB TESIRINE IN CYCLE 1)
- RESEARCH PRO00019932 ABDELRAHIM SWOG S1610 ARM 1
- RESEARCH PRO00019932 ABDELRAHIM SWOG S1610 ARM 2
- RESEARCH PRO00019932 ABDELRAHIM SWOG S1610 ARM 3
- RESEARCH PRO00020138 / CHANG ESR-17-13153
- RESEARCH PRO00020306 / RANDHAWA CCAT-FORMA-2102-HEM-101 COMBINATION (COHORTS 4, 5, 6, 8)
- RESEARCH PRO00020306 / RANDHAWA CCAT-FORMA-2102-HEM-101 SINGLE (COHORTS 1, 2, 3, 7)
- RESEARCH PRO00020361 RANDHAWA / ASTX727-02 (RANDOMIZED TO ASTX727 IN CYCLE 1)
- RESEARCH PRO00020361 RANDHAWA / ASTX727-02 (RANDOMIZED TO DECITABINE IN CYCLE 1)
- RESEARCH PRO00020441 ABDELRAHIM CCAT REPLIMUNE RPL-001-16 PHASE 1
- RESEARCH PRO00020441 ABDELRAHIM CCAT REPLIMUNE RPL-001-16 PHASE 2
- RESEARCH PRO00020572 ABDELRAHIM / SWOG 1613 ARM 2
- RESEARCH PRO00020607 / SURI (TESARO FIRST ADJUVANT/3000-03-005/ENGOT-OV44)
- RESEARCH PRO00020607 / SURI (TESARO FIRST NEO-ADJUVANT/3000-03-005/ENGOT-OV44)
- RESEARCH PRO00020627 ZAID NRG-GY006 ARM 1
- RESEARCH PRO00020627 ZAID NRG-GY006 ARM 2
- RESEARCH PRO00020780 SINGH INCMGA00012
- RESEARCH PRO00020925 ABDELRAHIM ASTELLAS PH3 GLOW
- RESEARCH PRO00021204 NIRAVATH DS8201-A-U302
- RESEARCH PRO00021210 NIRAVATH DS8201-A-U301
- RESEARCH PRO00021233 HEYNE XL 184-021
- RESEARCH PRO00021342 NIRAVATH DS8201-A-U303
- RESEARCH PRO00021475 / ABDELRAHIM / PANOVA-3
- RESEARCH PRO00021476 / ABDELRAHIM INCB 54828-302 INCYTE TRIAL (ARM)
- RESEARCH PRO00021476 / ABDELRAHIM INCB 54828-302 INCYTE TRIAL (GEM ARM)
- RESEARCH PRO00021842 DARCOURT IMMU-132-06
- RESEARCH PRO00021842 DARCOURT IMMU-132-06 COHORT 3
- RESEARCH PRO00021863 / ZHANG / PACIFIC 4
- RESEARCH PRO00021936 / ABDELRAHIM TELOTRISTAT LEXICON PHASE 2
- RESEARCH PRO00021957 / ESNAOLA ML41440 NEO-ADJUVANT ATEZOLIZUMAB FOR NON-METASTATIC RESECTABLE HIGH-RISK CUTANEOUS MELANOMA
- RESEARCH PRO00022270 / ABDELRAHIM / ASTELLAS ISN 8951-CL-5201 ARM 1
- RESEARCH PRO00022270 / ABDELRAHIM / ASTELLAS ISN 8951-CL-5201 ARM 2
- RESEARCH PRO00022762 / DARCOURT DORA ARM A
- RESEARCH PRO00022762 / DARCOURT DORA ARM B
- RESEARCH PRO00022835 / CHANG MCC-15-11083 T-CELL IMMUNE CHECKPOINT INHIBITION FOR HER2-NEGATIVE BREAST CANCER-PHASE 2 NEO-ADJUVANT TRIAL OF PEMBROLIZUMAB AND DECITIABINE COHORT A
- RESEARCH PRO00022835 / CHANG MCC-15-11083 T-CELL IMMUNE CHECKPOINT INHIBITION FOR HER2-NEGATIVE BREAST CANCER-PHASE 2 NEO-ADJUVANT TRIAL OF PEMBROLIZUMAB AND DECITIABINE COHORT B
- RESEARCH PRO00022852 / BERNICKER PISCES TAVO PLUS ELECTROPORATION WITH PEMBROLIZUMAB (PHASE 2)
- RESEARCH PRO00022968 / KAMAT / NRG-GY018
- RESEARCH PRO00023053 / RANDHAWA ALLIANCE A041501 PHASE III ARM I
- RESEARCH PRO00023053 / RANDHAWA ALLIANCE A041501 PHASE III ARM II
- RESEARCH PRO00023091 / NIRAVATH IMMU-132-09 SACITUZUMAB GOVITECAN PHASE 3 ARM A
- RESEARCH PRO00023091 / NIRAVATH IMMU-132-09 SACITUZUMAB GOVITECAN PHASE 3 ARM B
- RESEARCH PRO00025139 / PINGALI SGN35-015 BRENTUXIMAB VEDOTIN PHASE 2 PART E
- RESEARCH PRO00025139 / PINGALI SGN35-015 BRENTUXIMAB VEDOTIN PHASE 2 PART F
- RESEARCH PRO00025435 / PINGALI SGN35-028 BRENTUXIMAB VEDOTIN PHASE 2 SINGLE ARM
- RESEARCH PRO00026231 / NIRAVATH BO41843 ROCHE PHASE III RANDOMIZED DOUBLE-BLIND
- RESEARCH PRO00027370 / NAIR EA5163/S1709 INSIGNA ARM A 1ST LINE
- RESEARCH PRO00027370 / NAIR EA5163/S1709 INSIGNA ARM A 2ND LINE
- RESEARCH PRO00027370 / NAIR EA5163/S1709 INSIGNA ARM B 1ST LINE
- RESEARCH PRO00027370 / NAIR EA5163/S1709 INSIGNA ARM B 2ND LINE
- RESEARCH PRO00027370 / NAIR EA5163/S1709 INSIGNA ARM C 1ST LINE INDUCTION
- RESEARCH PRO00027370 / NAIR EA5163/S1709 INSIGNA ARM C 1ST LINE MAINTENANCE
- RESEARCH PRO00029163 / JAIN NSABP B-60 DS8201-A-U305 PHASE 3 SCREENING
- RESEARCH PRO00029163 / JAIN NSABP B-60 DS8201-A-U305 RANDOMIZED PHASE 3 ARM A
- RESEARCH PRO00029163 / JAIN NSABP B-60 DS8201-A-U305 RANDOMIZED PHASE 3 ARM B
- RESEARCH PRO00030861 / ZHANG / NRG-LU005 ARM 1
- RESEARCH PRO00030861 / ZHANG / NRG-LU005 ARM 2
- RESEARCH PRO00031036 / ZHANG BGB-A317-A1217-301 (ADVANTIG-301) ARM A OPTION 2 RANDOMIZED PHASE 3 NON-SMALL CELL LUNG CANCER
- RESEARCH PRO00031036 / ZHANG BGB-A317-A1217-301 (ADVANTIG-301) ARM B OPTION 2 RANDOMIZED PHASE 3 NON-SMALL CELL LUNG CANCER
- RESEARCH PRO00031036 / ZHANG BGB-A317-A1217-301 (ADVANTIG-301) ARM C OPTION 2 RANDOMIZED PHASE 3 NON-SMALL CELL LUNG CANCER
- RESEARCH PRO00031036 / ZHANG BGB-A317-A1217-301 (ADVANTIG-301) SCREENING OPTION 2 RANDOMIZED PHASE 3 NON-SMALL CELL LUNG CANCER
- RESEARCH PRO17580 DARCOURT – SGN22E-001
- RESEARCH PRO17598 NIRAVATH OBESITY STUDY ARM 1
- RESEARCH PRO17598 NIRAVATH OBESITY STUDY ARM 2
- RESEARCH PRO17598 NIRAVATH OBESITY STUDY ARM 3
- RESEARCH PRO18449 PATEL SWOG S1418 / BR006 ARM 1: OBSERVATION
- RESEARCH PRO18449 PATEL SWOG S1418 / BR006 ARM 2: MK-3475 (PEMBROLIZUMAB)
- RESEARCH PRO19178 NIRAVATH / DS8201-A-U201 PART 1: DOSE FINDING & PART 2 STAGE
- RSH IP/ OP PRO00036433 / SGN70-101 / TREATMENT
- RSH OP PRO00035986 / EA9152 / BASELINE/SCREENING
- RSH OP PRO00036433 / SGN70-101 / SCREENING / BASELINE
- RSH OP PRO00036788/CAMBRIA-1 / ARM A
- RSH OP PRO00036788/CAMBRIA-1 / ARM B /CAMIZESTRANT
- RSH OP PRO00036788/CAMBRIA-1 / SCREENING
- RSH OP PRO00037396 – NRG-GY026 / ARM 1
- RSH OP PRO00037396 – NRG-GY026 / ARM 2
- RSH OP PRO00037396 – NRG-GY026 / ARM 3
- RSH OP PRO00037917 / BR23-001 ARM 1
- RSH OP PRO00037917 / BR23-001 ARM 2
- RSH OP PRO00037917 / BR23-001 SCREENING
- RSH OP PRO00038062 CAMBRIA-2 / ARM A
- RSH OP PRO00038062 CAMBRIA-2 / ARM B /CAMIZESTRANT
- RSH OP PRO00038062 CAMBRIA-2 /SCREENING
- RSH PRO00036343 / IMCGP100-203 / BASELINE SCREENING
- Therapy_Plan_HM BARIATRIC INFUSION
- Therapy_Plan_THERAPEUTIC APHERESIS – PHOTOPHERESIS
- Therapy_Plan_CAGT- ECULIZUMAB (SOLIRIS) FOR AHUS
- Therapy_Plan_CAGT- BORTEZOMIB (VELCADE) INJECTION
- Therapy_Plan_CAGT- ZOLEDRONIC ACID (ZOMETA) INFUSION
- Therapy_Plan_CAGT- IVIG INFUSION
- Therapy_Plan_CAGT- ECULIZUMAB (SOLIRIS) FOR PNH
- Therapy_Plan_CAGT- INTRAVENOUS FLUID (IV)
- Therapy_Plan_CAGT- ALLO DAILY ORDERS
- Therapy_Plan_CAGT- AUTO DAILY ORDERS
- Therapy_Plan_CAGT- CLINIC PROCEDURE W CONSCIOUS SEDATION
- Therapy_Plan_IVIG BOOSTER INFUSION
- Therapy_Plan_CAGT- COMMON ORDERS
- Therapy_Plan_CAGT- DONOR LEUKOCYTE INFUSION (DLI)
- Therapy_Plan_CAGT- FEMORAL LINE PLACEMENT W SCC (DONOR CENTER)
- Therapy_Plan_CAGT- DONOR EVALUATION (NMDP/SIBLING)
- Therapy_Plan_CAGT- POST TRANSPLANT IMMUNIZATIONS
- Therapy_Plan_CAGT- NEUPOGEN STEM CELL MOBILIZATION (DEFAULT PT SUPPLIED)
- Therapy_Plan_CAGT- STEM CELL MONITORING (DEFAULT PT SUPPLIED)
- Therapy_Plan_CAGT- MOZOBIL STEM CELL MOBILIZATION
- Therapy_Plan_CAGT- PRE-TRANSPLANT WORKUP
- Therapy_Plan_IVIG INFUSION 0.5 GM/KG FOR KIDNEY TRANSPLANT (MAX 70 GRAMS)
- Therapy_Plan_HEMODIALYSIS THERAPY PLAN
- Therapy_Plan_TRANSIENT HEMODIALYSIS THERAPY PLAN
- Therapy_Plan_HEPATITIS B IMMUNE GLOBULIN (HBIG) INFUSION
- Therapy_Plan_VALPROATE SODIUM (DEPACON) INFUSION
- Therapy_Plan_IRON DEXTRAN COMPLEX (INFED) INFUSION
- Therapy_Plan_VEDOLIZUMAB (ENTYVIO) INFUSION
- Therapy_Plan_SOLIRIS FOR AHUS (ECULIZUMAB)
- Therapy_Plan_PENTAMIDINE (NEBUPENT) INHALATION
- Therapy_Plan_FERRIC GLUCONATE (FERRLECIT) INFUSION
- Therapy_Plan_CYCLOPHOSPHAMIDE (CYTOXAN) INFUSION
- Therapy_Plan_ARANESP (DARBEPOETIN)
- Therapy_Plan_INTRAVENOUS FLUID (IV) INFUSION
- Therapy_Plan_DENOSUMAB (XGEVA) INJECTION
- Therapy_Plan_ZOLEDRONIC ACID (ZOMETA) INFUSION
- Therapy_Plan_IRON SUCROSE COMPLEX (VENOFER) INFUSION
- Therapy_Plan_BLANK THERAPY PLAN
- Therapy_Plan_CEREZYME (IMIGLUCERASE) INFUSION
- Therapy_Plan_BELATACEPT (NULOJIX) MAINTENANCE INFUSION
- Therapy_Plan_VITAMIN B12 (CYANOCOBALAMIN) INJECTION
- Therapy_Plan_GOSERELIN (ZOLADEX) SQ INJECTION
- Therapy_Plan_LEUPROLIDE (LUPRON DEPOT) IM INJECTION – MALE
- Therapy_Plan_SOLIRIS FOR PNH (ECULIZUMAB)
- Therapy_Plan_ROMIPLOSTIM (NPLATE) SQ INJECTION
- Therapy_Plan_FILGRASTIM (NEUPOGEN) SQ INJECTION
- Therapy_Plan_FILGRASTIM (ZARXIO) SQ INJECTION
- Therapy_Plan_OCTREOTIDE DEPOT (SANDOSTATIN LAR) IM INJECTION
- Therapy_Plan_LANREOTIDE (SOMATULINE DEPOT) SQ INJECTION
- Therapy_Plan_PEGFILGRASTIM-JMDB (FULPHILA) SQ INJECTION
- Therapy_Plan_DEXAMETHASONE (DECADRON) INFUSION
- Therapy_Plan_CENTRAL VENOUS CATHETER MAINTENANCE
- Therapy_Plan_DEFEROXAMINE (DESFERAL) INFUSION
- Therapy_Plan_BACLOFEN (LIORESAL) INTRATHECAL INJECTION TRIAL
- Therapy_Plan_THERAPEUTIC PHLEBOTOMY
- Therapy_Plan_PENTAMIDINE (PENTAM) INFUSION
- Therapy_Plan_CRYOPRECIPITATE TRANSFUSION
- Therapy_Plan_FRESH FROZEN PLASMA TRANSFUSION
- Therapy_Plan_PLATELET TRANSFUSION
- Therapy_Plan_BLOOD TRANSFUSION
- Therapy_Plan_EPOETIN ALFA (PROCRIT) INJECTION NON-ONCOLOGY
- Therapy_Plan_INFLIXIMAB MAINTENANCE INFUSION
- Therapy_Plan_IVIG BOOSTER (MULTI-DAY) INFUSION
- Therapy_Plan_METHOTREXATE IM INJECTION (ONCE)
- Therapy_Plan_IVIG INFUSION 1 GM/KG FOR KIDNEY TRANSPLANT
- Therapy_Plan_SOLUMEDROL INDUCTION 500 MG (METHYLPREDNISOLONE)
- Therapy_Plan_CYCLOPHOSPHAMIDE (CYTOXAN) INFUSION ONCE
- Therapy_Plan_CAGT- PALIFERMIN (KEPIVANCE) INJECTION
- Therapy_Plan_MICAFUNGIN (MYCAMINE) INFUSION
- Therapy_Plan_CIDOFOVIR (VISTIDE) INFUSION FOR KIDNEY TRANSPLANT
- Therapy_Plan_SILTUXIMAB (SYLVANT) INFUSION
- Therapy_Plan_MORPHINE INTRATHECAL INJECTION TRIAL
- Therapy_Plan_WINRHO SDF INJECTION
- Therapy_Plan_CYTOMEGALOVIRUS IMMUNE GLOBULIN (CYTOGAM) INFUSION
- Therapy_Plan_CIDOFOVIR (VISTIDE) INFUSION FOR CMV
- Therapy_Plan_POST SPLENECTOMY IMMUNIZATIONS
- Therapy_Plan_IVIG BOOSTER INFUSION (ST. JOHNS – DEFAULT PT SUPPLIED)
- Therapy_Plan_COSYNTROPIN (CORTROSYN) INJECTION
- Therapy_Plan_GILENYA (FINGOLIMOD) FIRST DOSE PROTOCOL (DR. SIMPSON)
- Therapy_Plan_THERAPEUTIC APHERESIS – LDL APHERESIS
- Therapy_Plan_THERAPEUTIC APHERESIS – PLATELET REDUCTION
- Therapy_Plan_THERAPEUTIC APHERESIS – RBC EXCHANGE
- Therapy_Plan_THERAPEUTIC APHERESIS – THERAPEUTIC PLASMA EXCHANGE
- Therapy_Plan_THERAPEUTIC APHERESIS – WBC REDUCTION
- Therapy_Plan_STEM CELL / DONOR LYMPHOCYTE COLLECTION
- Therapy_Plan_RHO(D) IMMUNE GLOBULIN (RHOGAM) INJECTION
- Therapy_Plan_USTEKINUMAB (STELARA) INDUCTION INFUSION
- Therapy_Plan_BASILIXIMAB (SIMULECT) INFUSION
- Therapy_Plan_LEUPROLIDE (ELIGARD) SQ INJECTION
- Therapy_Plan_TOCILIZUMAB (ACTEMRA) INFUSION
- Therapy_Plan_IVIG INDUCTION INFUSION 0.4 GM/KG DAILY X5
- Therapy_Plan_IVIG INDUCTION INFUSION 0.6 GM/KG DAILY X4
- Therapy_Plan_BELIMUMAB (BENLYSTA) INFUSION
- Therapy_Plan_INFLIXIMAB INFUSION
- Therapy_Plan_IVIG INFUSION 1 GM/KG FOR LUNG TRANSPLANT
- Therapy_Plan_IVIG INFUSION 0.5 GM/KG FOR LUNG TRANSPLANT
- Therapy_Plan_SOLUMEDROL INDUCTION 1000 MG (METHYLPREDNISOLONE)
- Therapy_Plan_SOLUMEDROL INDUCTION 1250 MG (METHYLPREDNISOLONE)
- Therapy_Plan_SOLUMEDROL BOOSTER WEEKLY 1000 MG (METHYLPREDNISOLONE)
- Therapy_Plan_SOLUMEDROL BOOSTER MONTHLY 1000 MG (METHYLPREDNISOLONE)
- Therapy_Plan_ABATACEPT (ORENCIA) INFUSION
- Therapy_Plan_GOLIMUMAB (SIMPONI ARIA) INFUSION
- Therapy_Plan_ZOLEDRONIC ACID (RECLAST) INFUSION
- Therapy_Plan_CERTOLIZUMAB PEGOL (CIMZIA) INJECTION 400 MG
- Therapy_Plan_PEGLOTICASE (KRYSTEXXA) INFUSION
- Therapy_Plan_FERRIC CARBOXYMALTOSE (INJECTAFER) 750 MG INFUSION
- Therapy_Plan_FERUMOXYTOL (FERAHEME) 510 MG INFUSION
- Therapy_Plan_PAMIDRONATE (AREDIA) INFUSION
- Therapy_Plan_DENOSUMAB (PROLIA) INJECTION
- Therapy_Plan_EPOETIN ALFA (PROCRIT) INJECTION ONCOLOGY
- Therapy_Plan_BLOOD & PLATELET TRANSFUSION
- Therapy_Plan_RESEARCH SCREENING PRO0009707 MTG-REIC-PC003 MILES
- Therapy_Plan_NEUROLOGY ONLY – MIGRAINE INFUSIONS
- Therapy_Plan_INTRAVENOUS ANTIBIOTICS THERAPY PLAN
- Therapy_Plan_LEUPROLIDE (LUPRON DEPOT) IM INJECTION – FEMALE
- Therapy_Plan_ACUTE HYPERSENSITIVITY GUIDELINES
- Therapy_Plan_NATALIZUMAB INFUSION EVERY 4 WEEKS
- Therapy_Plan_OCRELIZUMAB (OCREVUS) INFUSION
- Therapy_Plan_NUSINERSEN (SPINRAZA) FOR SPINAL MUSCULAR ATROPHY (SMA) LOADING DOSE
- Therapy_Plan_NUSINERSEN (SPINRAZA) FOR SPINAL MUSCULAR ATROPHY (SMA) MAINTENANCE DOSE
- Therapy_Plan_USTEKINUMAB (STELARA) SUBCUTANEOUS INJECTION FOR PSORIASIS
- Therapy_Plan_PATISIRAN (ONPATTRO) INFUSION
- Therapy_Plan_USTEKINUMAB (STELARA) SUBCUTANENOUS INJECTION FOR CROHN DISEASE (MAINTENANCE)
- Therapy_Plan_STANDARD 4-HOUR IOHEXOL (OMNIPAQUE) CLEARANCE FOR MEASURING GFR
- Therapy_Plan_RITUXIMAB (RITUXAN) – SMITH 1101 RHEUMATOLOGY
- Therapy_Plan_ULTOMIRIS FOR PNH (RAVULIZUMAB-CWVZ)
- Therapy_Plan_CRIZANLIZUMAB (ADAKVEO) INFUSION
- Therapy_Plan_INFLIXIMAB-DYYB (INFLECTRA) INFUSION
- Therapy_Plan_LUSPATERCEPT (REBLOZYL) INJECTION EVERY 3 WEEKS
- Therapy_Plan_ORITAVANCIN (ORBACTIV) INFUSION
- Therapy_Plan_TEPROTUMUMAB INFUSION
- Therapy_Plan_RITUXAN-PVVR (RUXIENCE) – SMITH 1101
- Therapy_Plan_CASIRIVIMAB-IMDEVIMAB INFUSION
- Therapy_Plan_EPTINEZUMAB (VYEPTI) INFUSION
- Therapy_Plan_OUTPATIENT ELECTROLYTE REPLACEMENT
- Therapy_Plan_DESMOPRESSIN 0.3 MCG/KG INFUSION FOR STIMULATION TEST (MAX DOSE 20 MCG)
- Therapy_Plan_RETACRIT (EPOETIN ALFA-EPBX)
- Therapy_Plan_ANIFROLUMAB (SAPHNELO) INFUSION
- Therapy_Plan_AVALGLUCOSIDASE ALFA-NGPT INFUSION
- Therapy_Plan_ORITAVANCIN (KIMYRSA) INFUSION
- Therapy_Plan_RITUXIMAB-ABBS (TRUXIMA) – SM 1101
- Therapy_Plan_EFGARTIGIMOD ALFA (VYVGART) INFUSION
- Therapy_Plan_VEDOLIZUMAB (ENTYVIO) INFUSION – LOADING DOSE ONLY
- Therapy_Plan_BEVACIZUMAB INFUSION EVERY 21 DAYS
- Therapy_Plan_DEGARELIX SUBCUTANEOUS INJECTION (LOADING DOSE ONLY)
- Therapy_Plan_DEGARELIX SUBCUTANEOUS INJECTION (LOADING & MAINTENANCE)
- Therapy_Plan_RISANKIZUMAB-RZAA (SKYRIZI) INFUSION
- Therapy_Plan_GROWTH HORMONE SUPPRESION TEST
- Therapy_Plan_INCLISIRAN (LEQVIO) SUBCUTANEOUS INJECTION
- Therapy_Plan_GLUCAGON STIMULATION TEST
- Therapy_Plan_DESMOPRESSIN STIMULATION TEST
- Therapy_Plan_VUTRISIRAN (AMVUTTRA) SUBCUTANEOUS INJECTION
- Therapy_Plan_LONG 10-HOUR IOHEXOL (OMNIPAQUE) CLEARANCE FOR MEASURING GFR
- Therapy_Plan_BENRALIZUMAB (FASENRA) SQ EVERY 4 WEEKS
- Therapy_Plan_BENRALIZUMAB (FASENRA) SQ EVERY 8 WEEKS (MAINTENANCE)
- Therapy_Plan_ROMOSOZUMAB (EVENITY) SQ EVERY 4 WEEKS
- Therapy_Plan_RESEARCH PRO00024239 / GABER ISATUXIMAB INFUSION
- Therapy_Plan_CARFILZOMIB (KYPROLIS) FOR AMR
- Therapy_Plan_ETESEVIMAB-BAMLANIVIMAB INFUSION
- Therapy_Plan_RITUXIMAB 1000 MG FOR RHEUMATOLOGY
- Therapy_Plan_RITUXIMAB-ABBS (TRUXIMA) 375 MG/M2
- Therapy_Plan_RITUXIMAB-ABBS (TRUXIMA) 375 MG/M2 – NEUROLOGY/RHEUMATOLOGY
- Therapy_Plan_RITUXIMAB-ABBS (TRUXIMA) 500 MG
- Therapy_Plan_RITUXIMAB-ABBS (TRUXIMA) ONCE
- Therapy_Plan_CASIRIVIMAB-IMDEVIMAB SUBQ INJECTION
- Therapy_Plan_THYMOGLOBULIN FOR KIDNEY TRANSPLANT REJECTION
- Therapy_Plan_FERUMOXYTOL (FERAHEME) 1020 MG INFUSION
- Therapy_Plan_FERRIC CARBOXYMALTOSE (INJECTAFER) 15 MG/KG INFUSION
- Therapy_Plan_BEZLOTOXUMAB (ZINPLAVA) INFUSION
- Therapy_Plan_MONOFERRIC INFUSION
- Therapy_Plan_ZOLEDRONIC ACID (ZOMETA) INFUSION EVERY 6 MONTHS
- Therapy_Plan_HEMATOLOGY LAB THERAPY PLAN
- Therapy_Plan_LEQEMBI 10 MG/KG INFUSION
- Therapy_Plan_UPLIZNA THERAPY PLAN
- Therapy_Plan_BMT CERT EMERGENCY ORDERS
- Therapy_Plan_LEUPROLIDE DEPOT (LUPRON) Q12WEEKS
- Therapy_Plan_OP FULVESTRANT (INITIAL AND MAINTENANCE) INJECTION
- Therapy_Plan_ADAMTS13 (ADZYNMA) INFUSION
- Therapy_Plan_TOCILIZUMAB (CABMR) INFUSION
- Therapy_Plan_TOFERSEN (QALSODY) INTRATHECAL INJECTION
